



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review

Jahangir Emrani, Maryam Ahmed, Robert H. Newman, Misty D. Thomas, Nathan Mowa, Liesl JeffersFrancis, John C. Teleha



PII: S0141-8130(21)02329-1

DOI: <https://doi.org/10.1016/j.ijbiomac.2021.10.172>

Reference: BIOMAC 19685

To appear in: *International Journal of Biological Macromolecules*

Received date: 30 September 2021

Accepted date: 21 October 2021

Please cite this article as: J. Emrani, M. Ahmed, R.H. Newman, et al., SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review, *International Journal of Biological Macromolecules* (2021), <https://doi.org/10.1016/j.ijbiomac.2021.10.172>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

SARS-COV-2, Infection, Transmission, transcription, translation, proteins, and treatment: A Review

Contents

ABSTRACT.....	2
KEYWORDS.....	2
INTRODUCTION.....	2
Pathogenicity and Transmission	4
Genome Structure.....	6
Viral Replication	8
Entry into host cells.....	9
Translation of viral proteins.....	9
Transcription of the new genetic material	10
VIRAL PROTEINS.....	12
Structure and function of the SARS-CoV-2 Proteins.....	13
The S-protein.....	14
Changes in S-Protein due to mutations	19
E-Protein	19
M-protein.....	20
N-protein (nucleocapsid protein)	20
Viral Non-structural Proteins	21
Accessory Proteins	23
Target Receptors.....	24
Comparing SARS-CoV-2, SARS-CoV, and MERS-CoV receptor binding	26
STRATEGIES TO FIGHT SARS-COV-2	27
Spike Protein as Target for Inhibitors (Potential Drugs)	27
Chemistry of Selected Antiviral Compounds	28
Blood Pressure Drugs.....	34
Antibody-Based Therapies	36
SARS-CoV-2 Vaccines	38

SUMMARY AND CONCLUSIONS	39
AUTHOR INFORMATION	40
Corresponding Author	40
Author Contributions	40
Funding Sources	40
Notes	41
ABBREVIATIONS	41
REFERENCES	42

Jahangir Emrani*¹, Maryam Ahmed², Robert H. Newman³, Misty D. Thomas³, Nathan Mowa²,
Liesl JeffersFrancis³, John C. Teleha⁴

1. Department of Chemistry, North Carolina A&T State University, Greensboro, NC 27411

2. Department of Biology, Appalachian State University, Boone, NC 28608

3. Department of Biology, North Carolina A&T State University, Greensboro, NC 27411

2. Department of Biology, Appalachian State University, Boone, NC 28608

4. Department of Reference and Instruction, North Carolina A&T State University,
Greensboro, NC 27411

ABSTRACT

In this review, we describe the key molecular entities involved in the process of infection by SARS-CoV-2, while also detailing how those key entities influence the spread of the disease. We further introduce the molecular mechanisms of preventive and treatment strategies including drugs, antibodies, and vaccines.

KEYWORDS

Enzymes, Proteins, Peptides: Nucleic Acids, DNA, RNA, Drugs, Vaccines, SARS-COV-2, COVID-19, CORONA Virus, Epidemiology, Antibody, Transmission

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as “the novel coronavirus” due to genome variation relative to previously identified coronaviruses, is a positive sense RNA virus and the etiological agent of COVID-19. SARS-CoV-2 is a member of

the viral family, *Coronaviridae*, and subfamily, *Coronavirinae*, which are large, enveloped, single-stranded RNA viruses between 65-125 nm in diameter. Under electron microscopy, virions take on a roughly spherical shape and possess finger like extensions (glycoproteins), commonly referred to as spikes, on their surface (Figure 1).¹⁻⁴ These spikes resemble a crown (or a “corona” in Latin) that is the basis for the name of this family of viruses.⁵ Members of the subfamily *Coronavirinae* infect a variety of mammals, causing diverse clinical syndromes. They are grouped into four sub-groups based on sequence homology: alpha, beta, gamma and delta.⁶ To date, only seven coronaviruses infect humans. Four (two α -CoVs and two β -CoVs) cause mild cold-like illnesses but three, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and the recently discovered SARS-CoV-2 lead to serious or fatal disease. SARS-CoV and MERS-CoV emerged in the human population in 2002 and 2012, respectively, while SARS-CoV-2 emerged in 2019, leading to the current global pandemic.⁷⁻⁸ The 2002 SARS-CoV infected approximately 8,096 people, with a mortality rate of ~10%, whereas MERS-CoV infected over 2,500 people with a mortality rate of ~36%.⁹⁻¹² As of August 20, 2021, COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2, has infected over 210 million people and has killed close to 4.5 million people worldwide.¹³⁻¹⁵ Genomic analysis shows patterns of molecular divergence between SARS-CoV-2 and other coronaviruses, leading to a disease that is distinct from that of both SARS-CoV and MERS-CoV.^{5, 16} In this article, we will focus on describing the molecular basis of SARS-CoV-2 infection and antiviral drugs that target the virus. More detailed medical, epidemiological, and technologies used to identify and combat SARS-CoV-2 have been reviewed elsewhere.¹⁷⁻²⁶




Figure 1. Transmission electron micrograph of SARS-CoV-2 viral particle, isolated from a patient. Large red circles represent newly formed genome copies, and the small red balloons are new virions formed by budding at the interface of Golgi apparatus and endoplasmic reticulum. Credit: Yannick Schwab/EMBL in Ref 4.

Pathogenicity and Transmission

Like other coronaviruses, transmission of SARS-CoV-2 can occur primarily via infected respiratory droplets through direct, indirect, or close contact with infected individuals.²⁷ The virus targets and infects cells at the nasal, conjunctival, or oral mucosa once respiratory particles are inhaled or deposited on these locations. Receptors for SARS-CoV-2, which are found mainly in the human respiratory tract epithelium, facilitate virus entry and allow the virus to efficiently replicate and spread to various organs. Approximately five days after infection, the host is contagious and can transmit the virus easily through exhalation to potentially infect others. Symptoms associated with the virus infection are due to transient damage to susceptible cells in various organs, including the lung, intestines, kidneys, and blood vessels.²⁸

Infection by the virus triggers an initial inflammatory immune response during which white blood cells originating from the lymph nodes, such as helper T-cells and cytotoxic T-cells,

infiltrate to the site of infection to eliminate virus-infected cells²⁹. In addition, body temperature is raised, causing fever in an attempt to kill (i.e., denature) the virus while facilitating the immune response.³⁰⁻³¹ In patients who develop more severe disease, SARS-CoV-2 induces an aberrant host immune response. Overproduction of proinflammatory cytokines leads to a so-called “cytokine storm” which, if not remedied with the help of immunomodulators that regulate cytokine production or drugs like dexamethasone or blood thinners, can lead to death.³²⁻³⁵ This “cytokine storm”, can adversely affect several organs, including the liver, kidneys, and lungs.^{32, 36} The latter leads to breakdown of lung epithelial cells that line the air sacs in lungs, causing the air sacs to fill with fluid. This induces pneumonia and, in severe cases, acute respiratory distress syndrome (ARDS) that can cause lung failure and death. Studies have shown that levels of certain cytokines can be correlated with the severity of COVID-19 symptoms.³²

SARS-CoV-2 has an enhanced rate of transmission compared to the 2002 SARS-CoV. This is due to several characteristics, both of the virus (i.e., SARS-CoV-2) and its associated disease (i.e., COVID-19). For instance, active virus can remain viable on some surfaces for up to 9 days and in the indoor air for several hours, thus increasing the chances of exposure.³⁷ Likewise, differences in the severity and onset of symptoms of COVID-19 compared to SARS may lead to increased contact with infected individuals. For example, during the SARS-CoV epidemic of 2002, mortality rates were nearly twice that currently observed for COVID-19 pandemic (9.6% vs. 5.4%, respectively),^{10, 32} and infected individuals exhibited clear symptoms of respiratory distress almost immediately.³⁸⁻⁴⁰ In contrast, people infected with SARS-CoV-2 may not show signs of infection or illness for a week or longer, despite being contagious and shedding virus.⁴¹ Furthermore, asymptomatic individuals and people with mild symptoms may carry large amounts of virus in the upper respiratory tract, thus contributing to the rapid spread of SARS-CoV-2. In fact, in some situations, even after symptoms disappear, SARS-CoV-2-infected individuals may be shedding virus. In addition, re-infection may occur in specific cases, especially given that human coronaviruses are well equipped to subvert host immunity. For instance, the emergence of new variants of the virus that are more contagious and may carry

an increased risk of death, such as the South African variant (B.1.351), the UK variant (B.1.1.7), Indian variant (B.1.617.2), or the Brazil/Japan variant (P.1), suggest that SARS-CoV-2 is rapidly evolving mechanisms to increase contagiousness and subvert existing immune defenses.⁴²⁻⁴³ Clearly, additional information is needed to understand the global risks these new variants pose.

Genome Structure

After the initial sequencing of the SARS-CoV-2 genome in December 2019,¹⁶ the viral genome has been sequenced numerous times in order to detect mutations and identify variants.⁴⁴⁻⁴⁶ The genome of SARS-CoV-2 is comprised of a single-stranded RNA molecule housed inside a fatty acid membrane (Figure 2), known as the envelope.⁴⁷ The viral RNA, which is capped and polyadenylated, contains a 5' leader sequence of 70 bases, with 7-10 of those bases being transcription-regulatory sequences (TRS-L), and contains 13-15 ORFs. ORF1a is the longest region of the genome, carrying ~13,200 of the 29,674 bases in the sequence and encodes two genes, the papain-like protease and the 3CL protease. ORF1b, which overlaps with ORF1a (Figure 2),⁴⁷ encompasses bases 14,412 – 21,563 and encodes enzymes important for viral replication, such as a RNA-dependent RNA polymerase (RdRp), a helicase, and an endonuclease. Subsequent regions spanning from nucleotides 21,562-29,674 encode the structural proteins: the spike (S) protein, membrane (M) protein, envelope (E) protein, nucleocapsid (N) protein, and accessory proteins. Each ORF also has its own transcriptional-regulatory sequences (TRS), which are located immediately adjacent to the ORFs. The RdRp pauses when it crosses a TRS in the body (TRS-B) and switches the template to the TRS in the leader (TRS-L) during replication. This leads to discontinuous transcription and the fusion of negative (or complementary) strand RNAs that serve as templates for generation of genomic strand RNAs.


It is important to note that while most living organisms possess DNA as their fundamental genetic material, using RNA as the basis of the genome is unique to viruses.^{16, 48} There are several important differences between DNA and RNA that can affect their cellular function. For instance, RNA uses the nitrogenous base uracil in place of the thymine found in DNA.

Likewise, RNA nucleotides are composed of ribose sugar molecules that contain a hydroxyl moiety in the 2' position. In contrast, DNA contains a hydrogen atom at the 2' position, making it a deoxyribose. The absence of a hydroxyl at the 2' position causes the ribose sugar to adopt a C3'-endo sugar pucker vs. the C2'-endo pucker typically found in B-form DNA. As a consequence, rather than aligning neatly with the helical axis like in B-DNA, the nucleobases of RNA are tilted relative to the helical axis. This reduces the stability of complementary base pairs in RNA molecules, preventing RNA from forming long double helices. Instead, RNA tends to exhibit more single-stranded character than DNA, which is predominantly double-stranded. In DNA-based organisms, gene expression involves the transcription of DNA to RNA using RNA polymerase. RNA viruses, on the other hand, use RNA as templates for the transcription of additional copies of RNA. Due to this unique transcriptional requirement, virally encoded RdRps facilitate this process.

The genomic structure and content of SARS-CoV-2 has been shown to promote its survival in host cells and may contribute to the progression of disease. Coronaviruses, including SARS-CoV-2, contain cytosine-phosphate-guanine (CpG) nucleotides as part of their genome. CpG sequences allow cellular detection of viruses through association with toll-like receptor 9 (TLR9) in endosomes to trigger host type I interferon (IFN) antiviral immune response. This antiviral mechanism may be driven by the zinc-finger antiviral protein (ZAP), which restricts numerous viral pathogens by targeting CpG-rich RNA sequences. Interestingly, studies have shown that during replication of SARS-CoV-2, there is a selective pressure to lower CpG content as a means of evading the host immune response.⁴⁹ Interestingly, as another survival mechanism, the SARS-CoV-2 viral genome contains large-scale internal RNA base pairing, or genome-scale ordered RNA structures (GORS), which are associated with shielding viral RNA recognition in the host cell and may contribute to persistent mechanisms.⁴⁵

Built into the genome are also many secondary structures (SS) that are generated once the viral RNA has been synthesized and released into the cytoplasm of the host cell. The various forms of SS include hairpin-forming inverted repeats (IR), quadruplex sites, and a slippery sequence with a downstream pseudoknot, all of which are needed to equip the virus for

replication. For instance, a pseudoknot structure in ORF1ab, controls the frameshift during the overlapped transition of ORF1a and ORF1ab. This is known as programmed -1 ribosomal frameshift (-1 PRF) signal. The -1 PRF signal also contains a slippery sequence and linker region that play a role in protein translation.⁵⁰⁻⁵¹



Coronavirus genome and Proteins

Created in BioRender.com

Figure 2. The genome of SARS-CoV-2 contains over 29,000 bases and codes for 29 proteins. SARS-CoV-2 has four structural proteins: The proteins E and M that form the viral envelope, protein N binds to the RNA genome of SARS-CoV-2 and S protein which binds to host ACE2 receptor to initiate infection. The nonstructural proteins (NsPs) initially form as two long polypeptides which by the action of the virus' main protease (MP), Nsp5, aside from autocatalytically releasing itself, also releases the RNA-dependent RNA polymerase (RdRp), Nsp12. Because of its important role in the replication and transcription of the virus, MP can be targeted by antiviral drugs against SARS-CoV-2. Ref: 47

Viral Replication

Entry into host cells

All viruses, including SARS-CoV-2, enter host cells and efficiently modulate cellular factors to facilitate replication (Figure 3).⁵² SARS-CoV has been shown to infect cells in two ways: entry through endocytic mechanisms or through fusion of the viral envelope with the host cell plasma membrane.⁴⁶ In both cases, the spike protein subunits, S1 and S2, mediate attachment and entry by binding with the cell surface protein, angiotensin-converting enzyme 2 (ACE2). Recent structural data obtained via high resolution cryo-electron microscopy has revealed the simultaneous binding of two S glycoprotein trimers to an ACE2 dimer.⁵³⁻⁵⁴ Binding of the viral glycoproteins to ACE2 is further facilitated by heparan sulfate (HS). Finally, cleavage by the serine protease, TMPRSS2, promotes fusion with the host membrane. Other cellular proteases (e.g., furin) facilitate pH-dependent entry through the endocytic pathway. Studies have shown that the main entry routes are dependent on the presence of select proteases in specific cell types.⁵⁵ Once the virus has entered the host cell, the RNA genome is released into the cytoplasm in a process known as uncoating.⁵⁶

Translation of viral proteins

The release of the coronavirus genome into the host cytoplasm triggers a complex and highly regulated program of viral gene expression.⁴⁶ The two polyproteins (pp1a and pp1ab) are produced through translation of ORF1a and ORF1b from the genomic RNA. As mentioned above, pp1ab is expressed from a programmed-1 ribosome frameshift between ORF1a and ORF1b. The efficiency of the frameshift can be measured through ribosomal profiling and, in the case of SARS-CoV-2, pp1a is expressed at levels approximately 1.4-2.2 times greater than pp1ab.⁵⁷ Through co-translational and post-translation mechanisms, including processing by viral proteases nsp3 and nsp5, sixteen non-structural proteins are released from pp1a (nsp1-11) and pp1ab (nsp1-10, nsp12-16), of which fifteen compose the viral replication and transcription complex (RTC). The RTC includes RNA-processing and RNA-modifying enzymes as well as an RNA proofreading function. Of these enzymes, RNA synthesis is performed by the viral RdRp (nsp12) together with its two cofactors, nsp7 and nsp8, which has a 3'-terminal adenylyltransferase activity. The bifunctional nsp14 contains both a 3' to 5' exoribonuclease

(ExoN) domain and a guanine-N7-methyltransferase (N7-MTase) domain. Previous studies have shown that the ExoN function of nsp14 is critical for boosting longer-term replication fidelity for SARS-CoV. However, recently, it was revealed through biochemical evaluation of MERS-CoV and SARS-CoV-2 mutants that, for these viruses, ExoN plays a more direct role in RNA synthesis in addition to safeguarding the long-term fidelity of the viral genome.⁵⁸ In addition to these enzymes, non-structural proteins also provide important support functions to accommodate the RTC, such as modulating intracellular membranes, host immune evasion, and providing cofactors to facilitate replication. The 3' one third of the SARS-CoV-2 genome expresses genes for viral structural proteins and accessory proteins including the spike (S), nucleocapsid (N), membrane (M) and envelope (E) proteins. The S1 subunit of S protein mediates attachment to ACE2 while S2 promotes membrane fusion. Likewise, the N, M and E proteins are critical for different aspects of viral functioning, maturation and assembly and will be described in more detail in the sections below.⁵⁹

Transcription of the new genetic material

The early expression of viral genes leads to the biogenesis of viral replication organelles in the cytoplasm of infected cells that create a protected microenvironment for viral genomic RNA expression and the transcription of subgenomic mRNAs.⁴⁶ Viral genome replication is initiated by the transcription of full-length negative-sense genomic copies that serve as templates for the production of positive-sense genomic RNAs. These newly synthesized genomes also generate more nsps and RTCs or are packaged into progeny virions during the assembly process. In addition, all coronaviruses, including SARS-CoV-2, have a conserved leader sequence in their 5'-ends that function as *cis*-acting elements for the transcription of subgenomic mRNAs directed by viral RdRP. The TRS-L sequence described previously constitutes a signal for the transcription of subgenomic mRNA while each transcriptional unit on the genomic RNA are preceded by TRS-B, additional transcription regulatory elements.⁶⁰ Studies have also demonstrated that *trans*-acting factors encoded by the virus as well as cellular proteins play a role in subgenomic mRNA synthesis.⁶¹

Once subgenomic mRNAs are expressed, nsp16 in conjunction with nsp10, methylates the 5'-end of viral mRNAs to create a 5'-methyl-cap.⁶² This mechanism serves to not only promote translation of virally encoded messages by the host translational machinery, but it is also an essential strategy to protect the virus from the host immune response. RNA capping in coronaviruses involves several nonstructural proteins, including nsp13, nsp14, and nsp16. Nsp16, a cap ribose 2'O methyltransferase, is known to form a complex with nsp10 to convert mRNA species from the Cap-O ($^{me7}G_{\text{o}}\text{pppA}_1$) to the Cap-1 form ($^{me7}G_{\text{o}}\text{pppA}_{1m}$) by methylation of the 2'O ribose of the first nucleotide. Mass spectrometry studies have revealed that an essential antiviral factor, IFIT1, has high affinity for unmethylated Cap-O forms of RNA and impairs binding of eukaryotic translation initiation factors to 2'O-unmethylated RNA templates, resulting in the inhibition of translation.⁶³ Therefore, the specificity of IFIT1 for the Cap-O form of mRNA serves as a potent antiviral mechanism against viruses that lack 2'-O methyltransferase activity. Since coronaviruses actively generate Cap-1 forms of viral mRNAs, this not only promotes translation, but also serves as a viral strategy to avoid detection by the innate immune response.




Figure 3. Steps in SARS-CoV-2 viral replication. SARS-CoV-2 spike (S) glycoprotein and ACE2 on host cell surface interact and virus enters the host cell. Viral genomic RNA is released into the cytoplasm of the host cell, and the single-stranded positive-sense genome is transcribed to produce the viral papain-like protease (PLpro) and 3C-like serine protease (3CLpro), which cleave the two large polyproteins (pp1a and pp1ab) into 16 mature nonstructural proteins (NSPs), including two replicase polyproteins (RNA-dependent RNA polymerase (RdRp) and helicase (Hel)). Mature NSPs and the RdRp and Hel proteins are gathered into replication–transcription complexes (RTCs) for viral replication and transcription. RTCs synthesize negative-strand guide RNA (gRNA) and a set of subgenomic RNAs for viral replication and transcription. The newly produced subgenomic RNAs are translated into viral structural proteins such as the S, membrane (M), and envelope (E) proteins. These proteins are inserted into the membrane of the rough endoplasmic reticulum (ER) and then transported to the ER-Golgi intermediate compartment (ERGIC) to assemble with the N protein-encapsidated RNA to form viral particles. Virions are then released from the cell through exocytosis. The red boxes indicate where processes can be inhibited using named compounds in parenthesis.⁵² caption and figure from Ref 52.

VIRAL PROTEINS

The SARS-CoV-2 genomes contains 29,811 nucleotides and codes for a total of 29 different viral proteins (see Figure 2).⁶⁴ For comparison, the human genome contains 3.2 billion DNA nucleotides, which contains ~20,000 protein-coding genes.⁶⁵ Each of the SARS-COV-2 viral proteins are classified into one of three groups: 1) structural proteins, 2) non-structural proteins, or

3) accessory proteins (Table 1). Many structures of SARS-CoV-2 proteins have been described in the literature and have been compared with those of other coronaviruses.⁶⁶ The variation between these proteins accounts for the observed differences in each virus's contagiousness and infectivity in human cells.

Table 1. List of names, functions, and length of proteins*

Name	Name-Function	Length (aa)	Name	Name-Function	Length (aa)
ORF1ab	ORF1ab polyprotein	7,096	nsp14	3'-to-5' exonuclease, proof reading during RNA synthesis	527
ORF1a	ORF1a polyprotein	4,405	nsp15	endonuclease, cleaves RNA at polyuridylylate sites	346
nsp1	leader protein, inhibits host protein translation	180	nsp16	2'-O-ribose methyltransferase, in RNA capping	298
nsp2	nsp2, disrupts host cell cycle	638	nsp11	nsp11	13
nsp3	Protease, lowers host immune response, and host translation	1,945	S	surface glycoprotein	1,273
nsp4	nsp4	500	ORF3a	ORF3a	275
nsp5	3C-like proteinase	306	E	envelope protein	75
nsp6	nsp6	250	M	membrane glycoprotein	222
nsp7	nsp7, primer synthesis and RNA replication	83	ORF6	ORF6	61
nsp8	nsp8, primer synthesis and RNA replication	198	ORF7a	ORF7a	121
nsp9	nsp9, interacts with ORF5 protein to facilitate replication of virus	113	ORF7b	ORF7b	43
nsp10	nsp10, mRNA cap methylation	139	ORF8	ORF8	121
RdRp	RNA-dependent RNA polymerase, RNA replication	932	N	nucleocapsid phosphoprotein	419
nsp13	Helicase, activity during RNA replication	601	ORF10	ORF10	38

*Adapted from Kadam et al⁶⁴

Structure and function of the SARS-CoV-2 Proteins

Structural analysis of proteins and protein complexes can provide key insights into the molecular basis for their observed function. Therefore, researchers have examined the structure of several SARS-CoV-2 proteins and related complexes. Traditionally, X-ray

crystallography has been used to determine high resolution three-dimensional protein structures important for determining biological function and drug design.⁶⁷⁻⁶⁹ Though X-ray crystallography is a very detailed and powerful method, it is often limited by difficulties associated with protein crystalization caused by size and flexibility constraints. In addition, due to their flexibility, it is difficult to observe glycosylation patterns on the surface of crystallized proteins. Finally, since crystals require static positioning within a crystal lattice, it is very difficult to observe and predict conformational changes and protein dynamics without assuming movement between crystals in different static conformational states. Therefore, as an alternative technique, many structural biologists have begun to use cryogenic electron microscopy (cryo-EM) to determine protein structure.⁷⁰⁻⁷¹ During a cryo-EM experiment, the protein is deposited frozen onto a metal grid in a single molecule layer. The deposited layer is then irradiated with low energy electron beams and a 2-D image of the protein is obtained. By adding additional layers and using a computer to collect and sort the data, a 3D image of the protein is obtained. With cryo-EM, conformational changes and protein dynamics can also be recorded. In recent years, the quality of the images from cryo-EM experiments has improved to resolutions that are comparable to those obtained using crystallography.⁷²⁻⁷⁴ Because of these technologies, several structures of SARS-CoV-2 S-protein in a complex with the ACE2 receptor have been solved.^{8, 53, 75-76}

The S-protein

The S-protein of SARS-CoV-2 is a 150 kDa transmembrane protein embedded into the surface of the viral envelope. As mentioned previously, S-protein binds to ACE2 receptors on the surface of host cells to facilitate viral entry.^{8, 77} Several groups have solved the three-dimensional structure of the S-protein, thus providing valuable insights into its overall shape, plasticity, and specific target interactions.^{8, 53-54, 72, 75} The S-protein consists of an S1 subunit that binds the host cell receptor and an S2 subunit that is responsible for fusion of the viral envelope with host-cell membranes. In addition, S-protein has a receptor binding domain (RBD), composed of approximately 230 amino acids, that binds to specific sequences of the ACE2 receptor. The protein is fully glycosylated and forms a homotrimer made of A, B and C

chains embedded within the viral envelope (in Figure 9A and 9B, glycosylation sites are shown in dark grey). Interestingly, the S1 subunit has several domains that have been shown to vary in function depending on the specific viral strain. This variation leads to its ability to use alternative host cell recognition targets.

Recently a cryo-EM structure of the SARS-CoV-2 S-protein ectodomain trimer was solved.⁸
⁵⁴ The result suggests that the SARS-CoV-2 S-protein adopts conformations similar to those reported for both the SARS-CoV and MERS-CoV S-proteins. As observed in other β -coronavirus S-glycoproteins, the SARS-CoV-2 S1 subunit takes on a V-shape and harbors three human ACE2-recognition motifs in its closed state (known as the receptor binding domain or RBD shown in Figure 9C). Structural information shows that these motifs are buried, and therefore an opening of the structure is likely required for interactions with ACE2. This interaction would initiate a conformational change that would subsequently allow S2 protease cleavage, leading to membrane fusions and viral entry. In comparison to SARS- CoV, which uses S-protein residues Y422, L472, N479, D480, T487, and Y4911 for binding to ACE2, the SARS- CoV- 2 S-protein may use amino acids L455, F486, Q493, S494, N501, Y505 for binding to ACE2.⁷⁸⁻⁸¹ The differences in the amino acids promote stronger binding interactions between the SARS-CoV-2 S1 RBD and ACE2 receptor on the host cell. While cryo-EM is a beneficial strategy to elucidate the overall protein structure of S1, it is not an optimal method to identify the structure of the sugars that are covalently linked to the surface of the protein.⁸²⁻⁸⁴ The sugars play important roles in stabilizing the proteins to aid in folding. In addition, they have been shown to contribute to viral host immune evasion tactics. Because of their importance, the molecular composition and the structure of these sugars have been analyzed through mass spectrometry.⁸⁵

S-protein is heavily glycosylated, undergoing glycosylation on multiple asparagine (Asn) or serine (Ser) residues via N- and O-glycosylation, respectively. The formation of the N-glycan, which involves conjugation of N-acetylglucosamine to asparagine residues, is catalyzed by oligosaccharyltransferases present in the endoplasmic reticulum (ER) while the formation of O-glycans is mediated by O-GlcNAc transferase (OGT), likely in the ER or the Golgi apparatus.⁸⁶




Figure 4. The amine functional group of asparagine (Asn) functions as a nucleophile to promote N-linked glycosylation, in which a carbohydrate chain (e.g., N-acetyl glucosamine (GlcNAc)) is added to the protein chain. In general, a carbohydrate chain is added to an Asn residue when it is flanked C-terminally by X-serine or X-threonine, where X is any amino acid other than proline. In the case of O-linked glycosylation, the hydroxyl group of threonine or serine acts as the nucleophile to promote conjugation of GlcNAc or N-acetyl galactosamine (GalNAc). See ref 79

After being conjugated to Asn or Ser, N-acetyl glucosamine (GlcNAc) is further glycosylated by the enzyme GTase to produce D-galactose-GlcNAc.⁸⁷ (Figures 5-6) After this initial reaction, more sugars are added by other glycosyltransferases, eventually leading to the formation of long chains of various polysaccharides.




Figure 5. Addition of D-galactose to GlcNAc-serine. A similar reaction may be observed with threonine-N-acetylgalactosamine.




Figure 6. components of O-linked glycans

The SARS-CoV-2 S-protein has 22 putative N-linked glycosylation sites and 4 possible O-linked glycosylation sites (Figures 7A and 7B). Interestingly, mass spectral analysis shows differential glycosylation patterns in different cell types.⁸⁸⁻⁹¹ It appears that, depending on the tissue type, the overall level of glycosylation, as well as the relative ratios of N- to O-glycosylation, is different. In O-glycans, the sugar molecule is attached to the oxygen atom of serine (Ser) or threonine (Thr) of the protein (Figures 5&6) after the protein is synthesized. O-glycosylation occurs in the ER, Golgi apparatus, and even in cytoplasm. In humans, the S1 protein has been shown to be O-glycosylated on Thr323, Ser325, Ser673, Thr678 and

Ser686.⁹² The presence of O-glycosylation at Thr323 and Ser325 of the S1 subunit of SARS-CoV-2 has been correlated with the active structure for the protein, which leads to the biological function.⁹³ These differences can have a bearing on vaccine production, as they can influence how the S-protein interacts with ACE2 receptor.⁹⁴⁻⁹⁵




Figure 7. Structures of the SARS-CoV-2 S-glycoprotein. A) Cartoon diagram of the 3D structure of the S-glycoprotein solved using cryo-EM to 3.46 Å (PDB ID: 6VSB). The S-glycoprotein forms a trimer composed of an S1-subunit (pink), an S2-subunit B (green) and an S3-subunit (blue). This structure represents the prefusion conformation and was found to have 22 glycosylation sites (dark grey). B) 90° rotation of A. Here, the receptor binding domain (RBD) is located at the top of the structure. The RBD of the subunit C is boxed in black. C) Cartoon diagram of the RBD of the S-glycoprotein (green) bound to the host receptor ACE2 (orange) (PDB ID: 6M0J). This structure was solved to 2.45 Å using X-ray protein crystallography. D) Cartoon diagram of the SARS-CoV-2 RBD (green) bound to a SARS-CoV-2 specific antibody (the antibody heavy and light chains are colored dark blue and light blue, respectively). This structure was solved using X-ray crystallography to 2.85 Å (PDB ID: 7BWJ). It is important to note that the antibody binding site is at the same position as the ACE2 binding site, thereby blocking interactions between the virus and the host receptor. All figures were made using PyMol.

Changes in S-Protein due to mutations

Mutations are commonplace in viruses. As viruses replicate, their genome changes and the new virus carries the mutation to its offspring. Only some mutations produce more aggressive, more deadly diseases. Changes in the genome, causes changes in the viral proteins and since S-protein is the instrument of infection for SARS-COV-2, changes in the S-protein determines how easily virus can infect its host or how rapidly infection spreads among populations, or how fit an antibody is to the S-protein. Antibodies stick to the N-terminus domain and the S-protein while receptor binding domain (RBD) stick to the ACE-2 receptor at the surface of host cells. In B.1.1.7 Variant that was first detected in UK, nine mutations in the S-protein include N501Y which involves swap of asparagine to a tyrosine in RBD and deletion of 3 amino acids in positions 69, 70, and 144 in the N-terminal domain. A tighter binding of S-protein with ACE-2 due to this mutation makes the virus 50-70% more infectious. In the B.1.351 Variant which first appeared in South Africa, of the Nine amino acid swaps, three were involved in N501Y as in B.1.1.7 Variant, the other two were K417N (lysine to asparagine) and E484K (switching glutamic acid to lysine). These changes made the virus 50% more infectious than original variant. In P.1 Variant initially detected in Brazil, 11 mutations occur in S-protein which include N501Y and E484K seen in other variants and K417 which involves changing lysine to threonine. These mutations also increase the binding between RBD with ACE2 receptor on the host cells. In B.1.427 and B.1.429 Variants first detected in California, there are four mutations in the spike protein that include L452R, in which a leucine is swapped for arginine in the RBD. This Variant which was about 20% more aggressive is disappearing.⁹⁶ Delta and Kappa Variants first identified in India both have two mutations E484Q (glutamic acid E substituted by glutamine Q) and L452R (leucine L altered by arginine R). Delta in addition has T478K (threonine T replaced by lysine K) mutation. These mutations in S1 increases the binding affinity to ACE2 causing higher transmissibility and virulence.⁴⁴

E-Protein

The SARS-CoV-2 envelope protein (E-protein) is a 10 kDa protein with an N-terminal transmembrane domain and a C-terminal cytoplasmic tail.⁹⁷ In SARS-CoV, E-protein mediates

the budding and release of progeny viruses and also activates the host inflammasome. Studies have shown that the E-protein of SARS-CoV-2 is structurally and functionally similar to that of SARS-CoV and is highly conserved in their N-terminal regions.⁹⁸⁻⁹⁹ E-protein oligomerizes to form viroporins, which are small membrane-embedded proteins present on different viruses with ion-conducting properties. They form cation selective channels across the ER-Golgi intermediate compartment to aid in the viral production, maturation and release processes, which are regulated by ion homeostasis of cellular organelles.⁹⁹⁻¹⁰¹ This protein has also been found to influence folding of other proteins, which has an effect on the survivability of the host cells.¹⁰¹⁻¹⁰⁵

M-protein

The most abundant structural protein of coronaviruses is the membrane (M)-glycoprotein. M-protein is a membrane bound glycoprotein with protease activity and three transmembrane domains. The M-protein can interact with viral RNA and bind to the other structural proteins, including S-, E- and N-proteins.¹⁰⁶ Binding with M-protein helps to stabilize N-proteins to promote viral assembly. In addition, M-protein also aids the S-protein during the attachment phase and may be involved in immune evasion and pathogenicity functions of the virus.¹⁰⁷⁻¹⁰⁹ The C-terminus of the M-protein resides inside the cell with the N-terminus on the outside. The third transmembrane domain, common to all coronaviruses, contains both polar and non-polar ends. The presence of an N-terminal Ser at position 70 distinguishes the M-protein of SARS-CoV-2 from M-proteins of other CoVs and may have allowed SARS-CoV-2 to jump from bats to humans.¹¹⁰ An additional change is substitution of Ala for Thr at position 285 in SARS-CoV-2 M-protein, which may have increased the protease activity of the SARS-CoV-2 enzyme.⁸⁴

N-protein (nucleocapsid protein)

The N-protein has a molecular weight of 47 kDa and binds to gRNA. It has three domains, termed the N-terminal domain (NTD), central linker (CL), and C tail. This protein is involved in the replication and transcription of viral RNA and formation of the ribonucleoprotein (RNP) complex.¹⁰⁸ It also influences the host cell cycle to enhance viral multiplication.¹¹¹ The CTD

domain of SARS-CoV-2 N-protein, which is required for dimerization and oligomerization, interacts with the M-protein through the CL region.¹¹²

The NTD binds to RNA and contains a many positively-charged amino acids residues, which aid in binding the negatively-charged RNA. The amino acid sequence of SARS-CoV-2 N-protein is 90% similar to that of SARS -CoV.¹¹³ Most of the differences are due to the presence of these positively-charged amino acids in the SARS-COV-2, which are absent in other CoVs.

Viral Non-structural Proteins

In addition to the structural proteins, there are also 16 non-structural proteins (Nsps) in SARS-CoV-2, including polyproteins, nucleoproteins, and membrane proteins, each with varying functions (Figure 8). For instance, Nsp1 and Nsp2 are involved in modulating the immune response.¹¹⁴ Nsp1 has 180 amino acids and binds to the small subunit of the ribosome, stopping synthesis of antiviral proteins. In addition, Nsp1 halts all host protein synthesis by cleaving host mRNA.^{47, 115} As a result, production of type-1 interferons (which provide innate immunity) is halted, disabling the host defense mechanisms against the virus. Nsp2, on the other hand, influences cell division by altering the host cell cycle (Figure 3).¹¹⁶

Nsp3, or papain-like protease (PL^{pro}), is the largest of all Nsps and plays many roles. Along with Nsp5, it is responsible for cleavage of viral polyproteins into functional units.¹¹⁷⁻¹¹⁸ Nsp3 also plays a role in the onset of cytokine storm, assembly of viral particles, and, via interactions with Nsp4, in formation of double membrane vesicles.¹¹⁹ Finally, Nsp3 both inhibits the host enzyme poly-[ADP-ribose] polymerase (PARP), whose role is to block viral replication, and suppresses the expression of interferon genes (required for inhibition of viral infections).




Figure 8. The SARS-CoV-2 RNA dependent RNA polymerase (RdRp). The structure of the RdRp was solved to 2.95 Å using cryo-EM. A) Cartoon diagram of the RdRp (green) in complex with its required co-factors, NSP7 (blue), Nsp8-1 (light red) and Nsp8-2 (dark red). In addition, there are two molecules of Zn bound to the RdRp (PDB ID: 7BTF). The structure takes on a typical polymerase fold, with a thumb, palm and finger domain that cradles the RNA substrate during synthesis. B) Electrostatic surface diagram of Nsp12 alone. Here, the hole traversing between the domains is highly positively charged in order to provide a complementary binding site for the negatively charged RNA substrate. C) SARS-CoV-2 Nsp12/RNA complex solved using Cryo-EM to 3.53 Å (PDB ID: 6X2G). D) Cryo-EM structure solved to 2.5 Å of Nsp12, its cofactors, template RNA, and the drug Remdesivir. When Remdesivir is covalently incorporated into the RNA primer, it terminates chain elongation and therefore inhibits the polymerase activity of the enzyme (PDB ID: 7BV2). Figures made using PyMol.

Nsp9 is a single-stranded RNA-binding protein that plays a role in viral replication. Nsp12 is an RNA-dependent RNA polymerase (RdRp) and nsp13 is a helicase.^{80, 118} Both are essential for RNA replication. Nsp12, along with Nsp7 and Nsp8, recognize the RNA template and facilitate processivity.¹²⁰ (Figure 8A¹²¹ In SARS-CoV-2, it has been shown that the heterodimer Nsp7–Nsp8 and individual Nsp8 can bind with the RdRp.⁸²

The nsp13 helicase contributes to RNA synthesis and 5'-RNA capping by unwinding double stranded RNA in a 5'-3' direction to enable elongation by the RdRp. The RdRp (Nsp12) from SARS-COV-2 has the structure of a typical polymerase, which resembles a right hand with finger, thumb, and palm domains.¹²² When overlayed with the RdRp of SARS-CoV, there is only a root mean squared distance (rmsd) of 0.82 for 1,078 of the C-alpha for SARS-COV-2, indicating that there are very few structural differences between the two proteins.⁸² Despite these small differences, the amino acid sequence and the active sites of the RdRps from the two viruses are nearly identical.¹²³ This has enabled the rapid development of inhibitors against SARS-CoV-2 using the lessons learned from the previous inhibition studies on SARS-CoV.

Nsp14 is an exoribonuclease protein that acts as methyl transferase for N7 guanine in mRNA cap synthesis. For activation, Nsp14 requires Nsp10 to form a heterodimer.¹²⁴ Nsp15 is a nidoviral RNA uridylyate specific endoribonuclease (NendoU) that protects from attacks by host immune system.¹²⁵ Meanwhile, Nsp16 is a 2'-O-methyltransferase, which uses SAM for its methyl source. It complexes with nsp10 but has two S-adenosyl-L-methionine (SAM) binding sites of its own. Binding between SAM and nsp16 is mediated by both hydrophobic and ionic interactions.^{126,127,123,128,129}


Accessory Proteins

Accessory proteins are encoded primarily on the 3'-end of the viral RNA. They, like many of the other SARS-CoV-2 proteins, help to protect the virus against the host immune system. For instance, accessory proteins 3a and 7a are thought to be involved in induction of inflammation. The six accessory proteins, 3a, 6, 7a, 8a and 9b, are similar to those in SARS-COV. The only exception is 8b, which has an additional 37 amino acids not observed in SARS-COV.^{5, 130-131} Proteins.¹³² Because the structure of most SARS-CoV-2 proteins is very similar to the structure

of the proteins of coronaviruses studied previously,¹³³ similar techniques can be applied to the new virus during the development of the best inhibitors for target enzymes.^{71-72, 134}

Target Receptors

As alluded to above, respiratory droplets and aerosols carrying the SARS-CoV-2 virus produced by an infected person target the host nasal goblet epithelial cells, type II pneumocytes, and enterocytes cells^{64, 135-136} via interactions between ACE2 and the viral S-protein, which is primed by transmembrane serine protease 2 (TMPRSS2) located on the surface of the cells (Figure 2).^{36, 137}



The TMPRSS2 protein, which is also expressed in prostate, salivary gland, colon, and stomach, is a chymotrypsin family serine protease (492 aa) composed of three domains.^{64, 139-140} It mediates the cleavage of S-protein within the S1-S2 linker (R685) and at S2' (R815). The S1-S2 cleavage site is facilitated by the presence of several repeated basic arginine residues.^{64, 137, 141} Additional help is provided to the virus by Furin, a host cell protease that cleaves at the polybasic furin cleavage site (e.g., with the PQRESRRKK/GLF sequence of amino acids) in S-protein, promoting cell fusion and entry of the virus into human cells.^{64, 79, 135-136, 141} After cleavage at the S2' site, the fusion peptide is then inserted into the host membrane. The two HR regions, HR1 and HR2, in S2 domain form antiparallel α -helix bundles (6- HB). Once inside the host cell, the virus can effectively replicate and initiate the process of infection and disease development.^{136, 142} The RBD from SARS-CoV-2 S-protein has higher binding affinity (~5 kcal/mol) towards human ACE2 than the corresponding RBD from SARS-CoV S-protein, which is higher than its affinity for ACE2 from other animals.^{64, 143} This higher affinity, according to contact map analysis, is due to greater electrostatic interactions between the virus's S-protein and ACE2 receptor.¹⁴⁴ Computational alanine scanning analysis has identified key residues responsible for binding of the three RBDs of SARS-COV-2 with ACE2.¹⁴⁵ Accordingly, SARS-CoV-2 uses almost all (90%) of the tyrosine (Tyr) and glycine (Gly) residues that are present at its ACE2 interface for binding. Molecular dynamics simulation on membrane-bound ACE2 supports the presence of about seven additional hydrogen-bonded contacts between the SARS-CoV-2 RBD and ACE2.¹⁴⁶ Compared to human ATR1, preferential electrostatic interactions between ACE2 and the RBD of SARS-COV-2 are due to 7 additional hydrogen bonds, which is equivalent to ~3.4 kCal/mol of binding energy. According to mutagenesis analysis, residues 484 and 498 of the S-protein in SARS-CoV-2 are involved in recognizing human ACE2.¹⁴⁷

As stated, in addition to the Type II alveolar cells of lungs, ACE2 and TMPRSS2 are also expressed in the outer layer of the nasal and esophagus epithelium, the absorptive enterocytes from ileum and colon, and cornea.^{36, 148-149} In fact, single-cell RNA sequencing has shown high

ACE2 mRNA expression in Type II alveolar cells of lungs, myocardial cells, esophagus upper and stratified epithelial cells, and digestive tract and kidneys.^{53, 150-152} The initial contact may also occur on the skin, throat, or in the gastrointestinal (GI) tract.^{36, 153-157}

Comparing SARS-CoV-2, SARS-CoV, and MERS-CoV receptor binding

The SARS-CoV-2 genome is different from all previously identified coronaviruses, including SARS-CoV and MERS-CoV. These differences likely account for differences in cellular targets, as SARS-CoV-2 targets host nasal epithelium in addition to many other organs, in contrast SARS-CoV, which does not target the nasal epithelium but targets lung, trachea/bronchus, stomach, small intestine, distal convoluted renal tubule, sweat gland, parathyroid, pituitary, pancreas, adrenal gland, liver and cerebrum.¹⁵⁸ The SARS-CoV-2 S-protein exhibits even less homology with the MERS-CoV S-protein, which recognizes dipeptidyl peptidase-4 (DPP-4) as a specific receptor for host cell entry (as opposed to ACE2).^{75, 141, 159-160}

Aside from molecular factors, other factors such as age, smoking, and gender may also influence the expression of ACE2 and TMPRSS2 in the organs and tissues and thus influence the severity and rate of infection of SARS-CoV-2.^{137, 161-162} There is evidence that by directly infecting macrophages and T cells, SARS-CoV represses the body's immunity. But it is not yet clear if this is also the case for SARS-CoV-2, as macrophages and monocytes in the lung do not express large number of the ACE2 receptors.¹⁶³

The SARS-CoV-2 genome sequence was first published in January 2020 and is 79.5% similar to the genome of SARS-CoV.^{66, 80, 164-165} Both SARS-CoV and SARS-CoV-2 have S-proteins that are nearly 80% identical in composition.¹⁶⁶⁻¹⁶⁹ Interestingly, the relatively small number of differences between the two S-proteins can greatly influence parameters such as affinity between the S-protein and its receptor (ACE2).¹⁷⁰⁻¹⁷¹ The increased affinity of S-protein for ACE2 allows SARS-CoV-2 to attach to human cells much more strongly than the SARS-CoV. This characteristic of SARS-CoV-2 enhances both the contagiousness and infectivity of the virus.^{54, 168} Importantly, for infection, viral S-protein binds to host ACE2, therefore people with increased numbers of ACE2 sites in their lungs are more susceptible to the infection by this virus.¹⁷² One additional characteristic that sets SARS-CoV-2 apart from other

coronaviruses is the presence of a furin cleavage site within the S-protein. Furin is a host cell protease and has been found to be important for S-protein-mediated cell-cell fusion and entry into human lung cells.^{79, 141}

STRATEGIES TO FIGHT SARS-COV-2

Strategies to fight SARS-CoV-2 include vaccines, drug repurposing, novel antivirals, and therapeutic antibodies.^{171, 173-176} For effective development, all these strategies require knowledge of the viral genome and/or proteins, along with an understanding of the basic biology of its replication cycle. To this end, interdisciplinary teams of scientists use computer modeling, structure determination, metabolism/pharmacokinetics, biochemical assays, and synthetic chemistry protocols to design and optimize effective therapeutics. As a result, some drugs have been designed to inhibit capsid formation through formation of van der Waals forces, hydrogen bonds, and electrostatic interactions with the capsid directly. Meanwhile, others change the forces that hold the capsid together, disrupting their ability to attach and enter host cells. Many of the non-structural proteins, including the S-protein, M-protein, and RdRp, are also targeted by small molecule inhibitors, which binding to the enzyme active site. In some cases, these drugs are already available. For instance, several *in silico* screening efforts have shown similarities between SARS-CoV-2 and other non-coronaviruses, enabling the use of a number of available antivirals and drugs that are currently on the market.¹⁷⁷⁻¹⁸⁰

Spike Protein as Target for Inhibitors (Potential Drugs)

Much of the current efforts in combating SARS-CoV-2 is focused on finding ways to block the interactions between ACE2 and the viral S-protein, sometimes through specialized maneuvering that stabilizes the spike.¹⁸¹ The difficulty in doing this is that ACE2 is also present on the cells in other parts of the body that are not targets of the virus. Therefore, non-tissue specific inhibition of ACE2 could lead to unwanted side effects.¹⁸²⁻¹⁸³ ACE2's physiological role in the cell is in the maturation of angiotensin, which is a hormone that controls blood pressure by regulating blood vessel constriction. Consequently, the inhibition of ACE2 can lead to several complications, including cardiovascular disease and hypertension.⁵³ As a result, alternative strategies are being explored to block the interaction between the SARS-

CoV-2 S-protein and ACE2 directly using therapeutic antibodies. The ideal therapeutic antibody would specifically bind the S-protein and prevent it from interacting with the ACE2 receptor, achieving a similar result as blocking ACE2 directly without the negative side effects.⁷⁷ Alternatively, designing small peptides or small molecules that bind to different subunits of the SARS-CoV-2 S-protein will prevent the subunits from interacting with ACE2 and entry of virus into the cell. As previously stated, the S-protein is initially cleaved into S1 and S2 subunits by the host cell protease, furin. S1 facilitates receptor binding by engaging with the host cell membrane while S2 provides structural support and regulates the fusion with the host's epithelial cell membrane. For this reason, blocking the cleavage of the S-protein could also be a potential strategy for inhibiting viral entry.^{3, 4, 77, 184-186}

Using knowledge gained from HKU1, a common cold virus, and MERS virus, scientists found two small loops of amino acids that held two α -helices in the spike together. When the S-protein binds to human cells, the coil-like structure is released and the two helices and one loop are elongated to bring the human cell and the virus close together for fusion. By adding up to six proline residues to the SARS-CoV-2 S-protein, scientists believe that they can prevent the “spring” from being released, which would prevent the fusion of SARS-CoV-2 with human cells.¹⁸¹

Chemistry of Selected Antiviral Compounds

Due to the relatively small size of the SARS-CoV-2 genome and recent rapid advances in whole genome sequencing technologies, scientists were able to sequence the genome of the SARS-CoV-2 rather quickly once it was isolated.^{80, 165} As a result, the sequence has been used to determine the primary structure (i.e., linear amino acid sequence) of the viral proteins. Once a protein's primary sequence has been determined, computational modeling programs can be used to deduce its secondary and tertiary structures. These programs are based largely on homology modeling (which uses the structures of closely related proteins to model the structure of the protein-of-interest). This is either in lieu of 3D structure determination, as discussed previously, or as a complement to confirm what was observed *in vitro*. Once a

putative structure is determined, different therapies can be designed to target the protein's active site and/or other protein surfaces important for enzyme function.¹¹⁸ Of course, similar strategies can be used once a *bona fide* structure of the enzyme-of-interest is solved experimentally using structural biology methods, such as X-ray crystallography, NMR spectroscopy or, more recently, cryo-EM. The structural information can, in turn, be used to develop drugs that target those proteins involved in infection, viral replication, or transmission of the disease. In the process, computer models of the viral proteins are constructed and their interactions with human proteins are studied at the molecular level.^{174, 187} At the same time, high-throughput screening may be performed for the compounds that look promising based on *in silico* docking studies.^{83, 179}

At the onset of the COVID-19 pandemic, a list of 50,000 compounds with potential antiviral properties was provided by the American Chemical Society (ACS) Central Science. The compounds were extracted from the CAS Registry, which contains 160 million compounds.¹⁸⁸ The identified compounds were anti-infective, enzyme inhibitors, or have shown an effect on the respiratory system.¹⁸⁹

Recently, the cryo-EM structure of the RdRP was determined (Figure 8).^{74, 82, 190} The structural information led to computational simulations (*in silico*) of the interactions between RdRp and potential drug candidates. Similarly, knowledge of the structure of the S-protein and main protease (M-protein or M^{pro}) has allowed for similar studies.^{82, 170, 191-192} To make these studies possible, computational resources around the world have been made readily available to COVID-19 researchers by major international computer centers inside and outside the U.S. during the COVID-19 pandemic.¹⁹³

In addition to *in silico* analysis, animal models have been used to model infection, including mice that express the necessary receptors and succumb to similar symptoms as humans.^{189, 194} SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. This affords the opportunity to devise appropriate treatments through docking studies.^{83, 135}

Researchers at Novartis had quickly discovered that the M^{pro} from SARS-CoV-2 (cysteine-main protease) was very similar to the protease from the previous corona viruses. This includes the active site cysteine, which serves as a target for identifying inhibitors. As a result, sixteen potential inhibitors were identified using computational methods.¹⁹⁵⁻¹⁹⁷ A select number of identified inhibitors were synthesized and tested in models. Chemical structures were then further refined based on the results of the inhibition studies. A new smaller set of inhibitors were then obtained and some of the final compounds have entered randomized clinical trials.¹⁹⁸⁻¹⁹⁹ Computational studies have suggested that lopinavir, oseltamivir, and ritonavir may bind to SARS-CoV-2 M^{pro}.¹⁹⁸⁻¹⁹⁹ A similar approach could be used to develop inhibitors for all other viral proteins, including RdRp and the S-protein. More recently, it was discovered that drug repurposing studies for COVID-19 provided compounds that were harmful to the body as their mechanism of action was misunderstood in the initial studies.²⁰⁰ As a result, some of such drugs like hydroxychloroquine, Amiodarone, and Sertraline, cause phospholipidosis in the infected host cells which mistakenly in the studies was correlated with antiviral efficacy.

As previously discussed, RdRp is responsible for replication of the viral RNA (Figure 8).²⁰¹ Remdesivir (See Table 2) (an inhibitor of this enzyme, was originally developed as anti-Ebola drug,²⁰²⁻²⁰⁵ and soon entered the Phase I clinical trial against COVID-19.²⁰⁵⁻²⁰⁶ In addition, remdesivir was tested in combination with chloroquine and the combination compared with chloroquine alone.^{194, 207-208} Remdesivir in combination with interferon beta was also shown to be effective against SARS-CoV-2.²⁰⁸⁻²⁰⁹ Based on clinical trial results, and the compassionate use of this drug,^{18, 203, 210} remdesivir received Emergency Use Authorization by the FDA.^{205, 211-214} However, similar studies conducted in China suggested that remdesivir did not offer any benefit compared to placebo.^{205, 215-217} Considering all the results, clinicians think of remdesivir as a helpful treatment for shortening recovery time but not a cure.^{215, 218} Phase III Clinical trials of RdRp inhibitors, are currently underway. Remdesivir was recently approved by FDA.^{205-206,}

213

Two other inhibitors of viral RdRp's, favipiravir and the ribonucleoside analog, EIDD-2801 (See Table 2), were originally developed against HIV and hepatitis B.²¹⁹⁻²²¹ In animals infected

with SARS-CoV and MERS-CoV, EIDD significantly reduced viral titer and loss of body weight. Also, *in vitro*, in primary human airway epithelial cells (HAECs), EIDD reduced SARS-CoV-2 reproduction in a dose-dependent manner.^{189, 222} Remdesivir (administered through IV) and EIDD-2801 (administered orally) both hamper viral replication by targeting RdRp.²²³ Interestingly, EIDD, unlike other antiviral compounds, cannot be overcome by resistance through mutations in the virus. EIDD-2801 has a pyrimidine as its base structure altered with a N-hydroxycytidine.




Figure 10. The oxime form of EIDD-1931 mimics uridine, matching up with adenosine (left), while the other tautomer mimics cytidine and matches up with guanosine (right).

The drug EIDD-1931 has two tautomers, one tautomer is an oxime that mimics uridine and base pairs with adenosine, the other tautomer mimics cytidine, and forms hydrogen bonds with guanosine.²²⁴ As a result, the RdRp incorporates EIDD-2801 into its genome. However, since EIDD-2801 can tautomerize, the RdRp erroneously reads EIDD-2801 as uridine instead of cytidine when it replicates. Incorporation of adenosine instead of guanosine is a mutation that becomes part of the viral genome and affects all future generations of the virus by dictating how viral genomes are synthesized and copied. Since all RNA-based viruses have RdRp enzyme, this drug should work on SARS-COV-2 and other similar viruses.²²⁴ However, in practice, initially it did not work, when monkeys were dosed with this drug in their GI, the CH₂OH group in the molecule of EIDD-2801 was phosphorylated and the phosphorylated drug was readily excreted without being absorbed to work against the virus. To prevent this, the CH₂OH group on the sugar moiety of the molecule was first converted to 2-methyl propionate (prodrug formation) before dosing. This protected the CH₂OH group against pre-mature phosphorylation. The 2-methyl propionate moiety of the prodrug is broken back into the

CH₂OH upon absorption and then along with two other hydroxyl groups is phosphorylated to make the active drug. EIDD-2801 is developed in the United Kingdom (UK) by Merck. Phase I clinical trials of EIDD-2801 began on April 10, 2020 in the UK.²²⁵ EIDD-2801 is recommended to be given to patients as soon as infection is detected. Because of its mechanism of action, this drug will work against many RNA viruses, including MERS-CoV, HIV, Ebola, H1N1, and SARS-CoV. However, since other compounds that are similar to EIDD-2801 have been linked to birth defects in animals, expecting mothers or those who intend to become pregnant should avoid this drug.²²⁶ Mechanism of incorporation of these drugs into RNA is shown in Figure 11.²²⁷





Figure 11. Comparison of the mechanism of actions of antiviral Remdesivir, favipiravir, EIDD-2801, and EIDD-1931 through incorporation into RNA.²²⁷

Other potential drugs under study against COVID-19 include interferon, ribavirin, tocilizumab, sarilumab, lopinavir, and chloroquine. To date, no benefit has been observed with lopinavir-ritonavir treatment of patients.^{118, 228-229}

As additional potentially useful drug target, protein kinases also have a crucial role in entry, spread, and replication of the virus. AK-1 inhibitors, caffeic acid and its ester, propolis, ketorolac, and triptolide may help patients by inhibition of these crucial stages of virus life

cycle. However, these compounds are not easily available to the body due to their solubility problems.^{176, 230} Cathepsin C inhibition has also been pursued as an option to save overburdened lungs in serious cases.²³¹ Structures of three such inhibitors, Brensocatib, Abu-Bip-CN, IcatC_{xpz41} are included in Table 2. In terms of mechanism, in the inhibitor compound containing nitrile group, the nitrile group is said to interact with the cysteine 234 of Cathepsin C, resulting in a thioimide complex and inhibition (Figure 12).²³¹














Thioimide complex

Figure 12. Interaction of Cysteine 234 and nitrile leads to the formation of a thioimide complex, which inhibits cathepsin C. See Ref 230.

Table 2. List of compounds tested against SARS-CoV-2 and their chemical structures*

Name of the compound	Chemical structure	Function	Reference
Camostat mesylate		protease inhibitor	137
PB28		replication of SARS-CoV-2 by inhibiting the translation of viral RNA, or by modulation cell signaling	232-233
Zotatifin		replication of SARS-CoV-2 by inhibiting the translation of viral RNA, or by modulation cell signaling	232-233
Cloperastine		antihistamines showed good antiviral properties	233
Clemastine		antihistamines showed good antiviral properties	233
Famotidine (Pepcid)		targets histamine H2 receptors which are abundant in all parts of the body release of histamine by the mast cells is blocked and the overreaction of immune system dampened	234 235

Remdesivir		inhibitors of viral RdRp's	
EIDD-2801		inhibitors of viral RdRp's	219-221
Favipiravir		inhibitors of viral RdRp's	219-221
Tautomers of EIDD-1931		Antiviral against RNA viruses	189
Dexamethasone		Suppresses the overreaction of the immune system	236
Hydroxychloroquine		Anti-malarial drug. Inhibits viral replication <i>in vitro</i> Now banned	237-240
Baricitinib		anti-inflammation, rheumatoid arthritis drug Could prevent the cytokine storm	241-243
Ruxolittinib		a cancer drug Could prevent the cytokine storm	241-243
Brensocatib			231
Abu-Bip-CN			231
IcatC _{xp241}			231

*Structures created with ChemDraw

Blood Pressure Drugs

Blood pressure drugs are thought to increase the expression of ACE2 receptors (though this idea has been disputed by more recent studies).²⁴⁴⁻²⁴⁶ Therefore, initially, it was thought that people taking these drugs would have an increased number of ACE2 receptors on their cell surfaces, thus providing more sites for the virus to attach and making the patient more susceptible to infection. However, more recent evidence suggests that blood pressure drugs actually protect patients against the induced lung injury, as described in more detail below.^{18,}

244, 247-248

Since COVID-19 is more serious disease in older patients, they are also more likely to take ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) for hypertension, heart disease, and cardiovascular disease. These drugs regulate the renin-angiotensin equilibrium. ACEIs prevent ACE1 from converting angiotensin I to angiotensin II. Angiotensin II controls lung injury and severe inflammation preventing angiotensin II from binding to its receptors. To

lower blood pressure, these drugs keep the level of angiotensin II at a desired level by effecting the renin-angiotensin equilibrium (Figure 13).^{244, 247} In the lungs, heart, kidneys, nose, and GI tract, ACE2 helps regulate the angiotensin II levels by shifting this equilibrium to the right or the left, as needed. For instance, when angiotensin II levels are too high, ACE2 converts angiotensin II to angiotensin 1-7, which is inactive. When angiotensin II levels are too low, more angiotensin II is produced.⁵³ If the level of angiotensin II gets too high, fibrous tissue will form in the heart, kidney, and lungs, which can lead to severe fibrosis in these organs. Antihypertensive drugs like captopril, Lisinopril, and losartan either stop the production of angiotensin II or make it inactive. Towards the beginning of COVID-19 pandemic, many scientists warned against using ACEIs and ARBs in COVID-19 patients,²⁴⁹ [even though a prolonged absence of these drugs could kill the patients by increasing their hypertension. Subsequently, it was discovered that using these drugs does not, in fact, harm COVID-19 patients].²⁴⁴ In fact, they may actually help. This is because, during COVID-19 infection, the virus binds to host ACE2 and occupies host ACE2 sites. As a result, the ACE2 needed to convert angiotensin II to angiotensin 1-7 is no longer available, causing angiotensin II levels to go up. The increase in angiotensin II levels causes cell death and injury in lung and heart. The injury in lung causes the release of cytokines (small proteins), which enhance the inflammation reaction and leads to more cell death.^{33, 35} Fibroblasts form scar tissues and pneumonia ensues, filling the lung with fluid. The blood pressure drugs stop all these negative consequences of angiotensin build-up by increasing the number of ACE2 sites, which help the patient by converting excess angiotensin II to angiotensin 1-7 through the removal of one amino acid from its molecule.

In a study on mice infected with SARS-CoV-2 virus, levels of angiotensin II increased while levels of ACE2 decreased. Giving the blood pressure drug, losartan, to the animals reduced injury. The effect of blood pressure drugs is under study about in 30 clinical trials. In related studies, to study the effect of ACE2 on viral infection, by making changes in the translation, ACE2 levels are lowered.²⁵⁰




Figure 13. Blood pressure is regulated by the renin-angiotensin system. To enter target cells, SARS-CoV-2 binds to ACE2, preventing it from breaking down Angiotensin II into angiotensin 1-7.

Antibody-Based Therapies

Antibodies are proteins of the immune system that bind to a specific antigen (such as virus before it infects a host cell). The process involves both the innate and adaptive immune responses.¹⁷¹ Antibodies bind to the antigens on the surface of infected cells (see Figure 14) and mark them for destruction by killer T cells. Among the SARS-CoV-2 and SARS-CoV proteins, the S-protein elicits an antibody response, as it resides on the external surface of the virus, while the structural proteins, M-, E-, and N-protein (in SARS-CoV) do not. As a result, over 90% of antibodies are directed against S-protein.^{188, 251} Antibodies are made of a constant region (which interacts with other host immune proteins) and a variable region (that targets the

specific antigen). The variable region is constructed to match the shape and chemical properties of their target antigen with high specificity. Construction of the variable region is under the instructions of genetic code through a process called VDJ recombination. One type of specific antibodies, “neutralizing antibodies” can be used as therapies where they capture antigens like bacteria and viruses to prevent them from infecting our cells. Neutralizing antibodies for therapy have been developed against COVID-19.²⁵²⁻²⁵⁴




Figure 14. Depiction of how antibodies block the spike protein of SARS-CoV-2, preventing the virus from attaching its spike protein to ACE2 receptors to initiate infection (Left).²⁵²⁻²⁵⁴ Four different ways that antibodies bind to receptor binding domain of spike protein from SARS-COV-2 virus (Right), [from Ref. 74]⁷⁴

Due to similarity of viruses, the antibody raised against the SARS-CoV S-protein can also prevent infection by binding S-proteins from SARS-CoV-2 and MERS-CoV.²⁵⁴⁻²⁵⁷ However, because the S-protein in SARS-CoV has fewer sugar moieties on its surface, antibody binding is weaker to the SARS-CoV-2 S-protein. As a result, for treatment purposes, antibodies are isolated from convalescent plasma collected from patients who recently recovered from COVID-19. Currently, scientists are working to identify the gene in the B cells that code for the SARS-CoV-2 antibody to then recombinantly express those genes as therapeutics. This approach has already worked in the case of SARS.^{26, 188}

In another approach used by Regeneron, genetically modified mice were injected with the S-protein. B cells were then isolated from the mouse and among the B cells, those that produced

the best monoclonal antibody were isolated, compared with best antibody from patients, and then mass produced through cell culture.²⁵¹ Palivizumab, a monoclonal antibody produced in this manner, is effective against respiratory syncytial virus. With financial support from the U.S. government, using VelociMouse technology, a mouse genetically modified to have human immune system, Regeneron developed monoclonal antibody against the S-protein of SARS-CoV-2, which received EUP from FDA approval.^{74, 258} Tychan, a company from Singapore, started its clinical trial in China. Working with AbCellera, Eli Lilly also developed its monoclonal antibody (Ly-CoV555), a neutralizing antibody, designed to prevent the SARS-CoV-2 from entering the cells. The antibody targets the S-protein of the virus and thus prevents infection by clearing the virus from the body. One out of three doses were given to people with mild symptoms of COVID-19 or placebo. In these studies, the rate of hospitalization in those patients who received the real dose was reduced to 1.1% compared to 6% for the placebo.²⁵⁹ Another antibody against S-protein (JS016) is a human monoclonal neutralizing antibody developed by Junshi Biosciences. When combined with Ly-CoV555, this product makes a strong antibody.²⁶⁰ Some of the difficulty for these techniques lies in scaling production. As a result, with the immediate threat of this viruses, it is important to note that these companies have been able to cut the time of the development and evaluation of these therapies from 10-12 months possibly to 5-6 months.²⁶¹

SARS-CoV-2 Vaccines

Vaccines trick our bodies to perceive it as an antigen and cause our immune system to mount an attack to destroy the antigen.²⁶² Body's defense is presented in the form of antibodies which are proteins created to match the structure of the antigen in addition to secondary defensive mechanisms involving T-cells. Close to 200 vaccine development programs have been working to create vaccines against SARS-COV-2 virus. Some like Moderna and Pfizer use mRNA as vaccine to generate antibody against the S-protein inside the human cells. mRNA delivers the order for the synthesis of the antibodies to the ribosome which is in charge of custom synthesis of desired proteins.²⁶³ Other programs use the S-protein itself as vaccine, or use the older method of creating vaccine using the whole inactivated virus. Vaccination of the

populations against SARS-CoV-2 has been successful in preventing the infection and death in many countries. However, some people refuse the vaccines while many do not have access to the vaccines. Initially, the major challenge for the vaccination, especially in the US was the creation and production of the vaccines. However, after vaccination of about 50% of the population, the challenge has shifted to convincing the unvaccinated people to accept the vaccine. In the meantime, the virus has sufficient hosts to mutate to new variants including alpha, beta, gamma, and delta. Emergence of newer variants resistant to current vaccines may require the development and production of booster vaccines.²⁶⁴

SUMMARY AND CONCLUSIONS

The fight against SARS-CoV-2 has been a major challenge for our best scientists, massive investments of pharmaceutical companies and governments, and our available technology. In a very short window of time, significant advances were made in finding ways to lessen the spread of the virus and prevent and treat the viral infection through therapeutics and vaccines. Understanding the mechanism of interaction between the viral S-protein and ACE2 along with the structure and function of the RdRp, M^{Pro}, viral RNA, and various proteases have been instrumental in discovering novel treatment methods.^{171, 265} We have seen that biochemically, SARS-CoV-2 shows higher affinity towards the ACE2 receptor compared to SAR-CoV. Despite this small difference, fortunately there are many similarity between these two viruses, which has facilitated the discovery and development of antibody therapies, and vaccines to tame the COVID-19 Pandemic.²⁵⁶ Vaccine development used many different techniques, some very new, but all focused on inducing the production of neutralizing antibodies against the spike protein in the body.²⁶⁶⁻²⁶⁹ In addition to developing vaccines, scientists also explored other potential strategies that have not been discussed here. They include targeting the viral proteases, therapies based on cytokines, and nucleic acids. Knowledge of these and other relevant technologies is essential, not only for fighting the SARS-CoV-2 of today, but also to combat future viruses and pathogens.

Despite development of so many prevention and treatment tools in a short time period, mutation in SARS-COV-2 virus RNA may lead to drastic changes in the viral genome and render all or some of these strategies useless.^{5, 16} Fighting a mutating virus is possible, but as experience has shown, may be challenging. Thus, the most effective way of combating the virus is to vaccinate the whole population and follow safety guidelines such as social distancing, wearing masks, sanitization, and contact tracing. However, experience has shown that for political or other reasons, these are not fully achievable.²⁷⁰⁻²⁷⁶

Just as in the case of the Spanish flu of 1918, SARS-COV-2 will continue to dominate the news for years to come. In fact, it is expected that this virus, like other viruses such as flu virus remain within the human population for the foreseeable future. As younger people acquire immunity, older adults will remain susceptible until herd immunity is established within the population. The potential for childhood vaccines for long-term protection as in the case of other childhood vaccines is still uncertain as we continue to understand the immune response of all segments of the population including children. In the meantime, new experimental treatments, along with social distancing and proper hygiene will be necessary in conjunction vaccines to protect the susceptible population. In the process, cooperation of national and international leaders is important for fighting the current pandemic.

AUTHOR INFORMATION

Corresponding Author

*E-mail: emrani@ncat.edu

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. ‡These authors contributed equally.

Funding Sources

Any funds used to support the research of the manuscript should be placed here (per journal style).

Notes

The authors declare no competing financial interest.

ABBREVIATIONS

3CLpro, 3C-like protease or main protease

ACE2, angiotensin-converting enzyme II

Ang, angiotensin

ARDS, acute respiratory distress syndrome

CatC, cathepsin C

CCR2, CC chemokine receptor 2

CCL2, CC chemokine ligand 2

CCR5, CC chemokine receptor 5

COVID-19, coronavirus disease 2019

CPG, CpG is shorthand for 5'—C—phosphate—G—3' [cytosine and guanine separated by one phosphate group]

E protein, envelope protein

ELISA, enzyme-linked immunosorbent assay

FP, fusion peptide

HA, hemagglutinin

HCoV, human coronavirus

HCV, hepatic C virus

HIV, human immune deficiency virus

HTS, high-throughput screen

IFA, immunofluorescence assay

IFN- β , interferon β

M protein, membrane protein

MERS-CoV, Middle East respiratory syndrome coronavirus

N protein, nucleocapsid protein

nsp, non-structural proteins

PCR, polymerase chain reaction

PLpro, papain-like protease

RAS, renin-angiotensin system

RdRp, RNA-dependent RNA polymerase

S protein, spike protein

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

SERMs, selective estrogen receptor modulators

SFKs, Src-family of tyrosine kinases

TCM, traditional Chinese medicine

REFERENCES

1. National Institute of Allergy and Infectious Diseases (NIAID). Integrated Research Facility (IRF). Novel coronavirus SARS-CoV-2. *flickr* [Online], 2020. <https://flic.kr/p/2iDwzAJ> (accessed July 2020).
2. Cortese, M.; Lee, J.-Y.; Hennies, J.; Mizzon, G.; Laketa, V.; Ruggieri, A.; Yannick Schwab; Bartenschlager, R., Integrative imaging reveals SARS-CoV-2 induced reshaping of subcellular morphologies. Cortese et al. In *Mendeley Data*, Elsevier: 2020; Vol. V1. DOI: 10.17632/8fc7fr8g63.1.
3. Cortese, M.; Lee, J.-Y.; Cerikan, B.; Neufeldt, C. J.; Oorschot, V. M. J.; Köhrer, S.; Hennies, J.; Schieber, M. L.; Ronchi, P.; Mizzon, G.; Romero-Brey, I.; Santarella-Mellwig, R.; Schorb, M.; Boermel, M.; Mocaer, K.; Beckwith, M. S.; Templin, R. M.; Gross, V.; Pape, C.; Tischer, C.; Frankish, J.; Horvat, N. K.; Laketa, V.; Stanifer, M.; Boulant, S.; Ruggieri, A.; Chatel-Chaix, L.; Yannick Schwab; Bartenschlager, R., Integrative Imaging Reveals SARS-CoV-2-Induced Reshaping of Subcellular Morphologies. *Cell Host & Microbe* **2020**, 28 (6), 853-866.e5. DOI: 10.1016/j.chom.2020.11.003.
4. European Molecular Biology Laboratory. Replication cycle of SARS-CoV-2 in 3D. *Healthcare-In-Europe.com* [Online], November 26, 2020. <https://healthcare-in-europe.com/en/news/replication-cycle-of-sars-cov-2-in-3d.html> (accessed August 20, 2021).
5. Shereen, M. A.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R., COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *Journal of Advanced Research* **2020**, 24 (July), 91-98. DOI: 10.1016/j.jare.2020.03.005.

6. Cui, J.; Li, F.; Shi, Z.-L., Origin and evolution of pathogenic coronaviruses. *Nature Reviews Microbiology* **2019**, 17 (3), 181-192. DOI: 10.1038/s41579-018-0118-9.
7. Guo, Y.-R.; Cao, Q.-D.; Hong, Z.-S.; Tan, Y.-Y.; Chen, S.-D.; Jin, H.-J.; Tan, K.-S.; Wang, D.-Y.; Yan, Y., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. *Military Medical Research* **2020**, 7, 11. DOI: 10.1186/s40779-020-00240-0.
8. Walls, A. C.; Park, Y.-J.; Tortorici, M. A.; Wall, A.; McGuire, A. T.; Veesler, D., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **2020**, 181 (2), 281-292, e1-e6. DOI: 10.1016/j.cell.2020.02.058.
9. Katsnelson, A., What we know about the novel coronavirus's proteins. *C&EN Global Enterprise* **2020**, 98 (15), 19-21. DOI: 10.1021/cen-09815-feature2.
10. Park, S. E., Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease 19). *Clinical and Experimental Pediatrics* **2020**, 63 (4), 119-124. DOI: 10.3345/cep.2020.07493.
11. Peiris, J. S. M.; Guan, Y.; Yuen, K. Y., Severe acute respiratory syndrome. *Nature Medicine* **2004**, 10 (12), S88-S97. DOI: 10.1038/nm1143.
12. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 *Emergencies Preparedness, Response* [Online], December 31, 2003. https://www.who.int/csr/sars/country/table2004_04_21/en/ (accessed July 2020).
13. Johns Hopkins University & Medicine. Home *Coronavirus Resource Center* [Online], 2021. <https://coronavirus.jhu.edu/> (accessed August 20, 2021).
14. World Health Organization. Coronavirus disease (COVID-19): Weekly epidemiological update and weekly operational update and situation reports *Coronavirus Disease (COVID-19) Pandemic: Situation Reports* [Online], 2021. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/> (accessed August 20, 2021).
15. World Health Organization WHO coronavirus (COVID-19) dashboard. <https://covid19.who.int/> (accessed August 20, 2021).
16. Tang, X.; Wu, C.; Li, X.; Song, Y.; Yao, X.; Wu, X.; Duan, Y.; Zhang, H.; Wang, Y.; Qian, Z.; Cui, J.; Lu, J., On the origin and continuing evolution of SARS-CoV-2. *National Science Review* **2020**, 7 (6), 1012–1023. DOI: 10.1093/nsr/nwaa036.
17. Neerukonda, S. N.; Katneni, U., A Review on SARS-CoV-2 virology, pathophysiology, animal models, and anti-viral interventions. *Pathogens* **2020**, 9 (6), 426. DOI: 10.3390/pathogens9060426.
18. Sanders, J. M.; Monogue, M. L.; Jodlowski, T. Z.; Cutrell, J. B., Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. *JAMA* **2020**, 323 (18), 1824-1836. DOI: 10.1001/jama.2020.6019.

19. Schoeman, D.; Fielding, B. C., Coronavirus envelope protein: current knowledge. *Virology Journal* **2019**, 16 (1), 69. DOI: 10.1186/s12985-019-1182-0.
20. Schoeman, D.; Fielding, B. C., Is there a link between the pathogenic human coronavirus envelope protein and immunopathology? A review of the literature. *Frontiers in Microbiology* **2020**, 11, 2086. DOI: 10.3389/fmicb.2020.02086.
21. Young, B. E.; Ong, S. W. X.; Kalimuddin, S.; Low, J. G.; Tan, S. Y.; Loh, J.; Ng, O.-T.; Marimuthu, K.; Ang, L. W.; Mak, T. M.; Lau, S. K.; Anderson, D. E.; Chan, K. S.; Tan, T. Y.; Ng, T. Y.; Cui, L.; Said, Z.; Kurupatham, L.; Chen, M. I.-C.; Chan, M.; Vasoo, S.; Wang, L.-F.; Tan, B. H.; Lin, R. T. P.; Lee, V. J. M.; Leo, Y.-S.; Lye, D. C.; Team, f. t. S. N. C. O. R., Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA* **2020**, 323 (15), 1488-1494. DOI: 10.1001/jama.2020.3204.
22. Zhang, J.; Xie, B.; Hashimoto, K., Current status of potential therapeutic candidates for the COVID-19 crisis. *Brain, Behavior, and Immunity* **2020**, 87 (July), 59-73. DOI: 10.1016/j.bbi.2020.04.046.
23. *Clinical virology*. 4th ed.; Richman, D. D.; Whitley, R. J.; Hayden, F. G., Eds. ASM Press: Washington, DC, 2017. DOI: 10.1002/9781683670674.
24. Carroll, K. C.; Pfaller, M. A.; Landry, M. L.; McAdam, A. J.; Patel, R. M. D.; Richter, S. S.; Warnock, D. W., *Manual of clinical microbiology*. 12th ed.; ASM Press: Washington, DC, 2019; Vol. 1-2.
25. Lostroh, P., *Molecular and cellular biology of viruses*. Taylor & Francis: Boca Raton, FL, 2019.
26. Moharana, S.; Khuntia, P.; Das, S. S.; Das, R.; Samantaray, P.; Mohanty, S. Evolution of experimental techniques & control measures in COVID-19 reservoir studies: A systematic review *International Journal of Innovative Science and Research Technology* [Online], 2020, p. 918-934. <https://www.ijisr.com/assets/upload/files/IJISRT20MAY713.pdf> (accessed June 2020).
27. Muralidar, S.; Amali, S. V.; Sekaran, S.; Krishnan, U. M., The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. *Biochimie* **2020**, 179 (December), 85-100. DOI: 10.1016/j.biochi.2020.09.018.
28. Gu, J.; Korteweg, C., Pathology and Pathogenesis of Severe Acute Respiratory Syndrome. *The American Journal of Pathology* **2007**, 170 (4), 1136-1147. DOI: 10.2353/ajpath.2007.061088.
29. Henry, B. M.; de Oliveira, M. H. S.; Benoit, S.; Plebani, M.; Lippi, G., Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. *Clinical Chemistry and Laboratory Medicine (CCLM)* **2020**, 58 (7), 1021-1028. DOI: 10.1515/cclm-2020-0369.

30. Cartmell, T.; Mitchell, D., The molecular basis of fever (Ch. 2.4). In *Techniques in the Behavioral and Neural Sciences: Handbook of Stress and the Brain, Part 2, Stress: Integrative and Clinical Aspects*, Steckler, T.; Kalin, N. H.; Reul, J. M. H. M., Eds. Elsevier: Amsterdam, 2005; Vol. 15, Pt. 2, pp 193-227. DOI: 10.1016/S0921-0709(05)80056-2.
31. Roth, J.; Blatteis, C. M., Mechanisms of fever production and lysis: Lessons from experimental LPS fever. *Comprehensive Physiology* **2014**, 4 (4), 1563-1604. DOI: 10.1002/cphy.c130033.
32. Liu, Y.; Zhang, C.; Huang, F.; Yang, Y.; Wang, F.; Yuan, J.; Zhang, Z.; Qin, Y.; Li, X.; Zhao, D.; Li, S.; Tan, S.; Wang, Z.; Li, J.; Shen, C.; Li, J.; Peng, L.; Wu, W.; Cao, M.; Xing, L.; Xu, Z.; Chen, L.; Zhou, C.; Liu, W. J.; Liu, L.; Jiang, C., Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury *National Science Review* **2020**, 7 (6), 1003–1011. DOI: 10.1093/nsr/nwaa037.
33. Jose, R. J.; Manuel, A., COVID-19 cytokine storm: The interplay between inflammation and coagulation. *The Lancet Respiratory Medicine* **2020**, 8 (6), e46–e47. DOI: 10.1016/S2213-2600(20)30216-2.
34. Wu, C.; Chen, X.; Cai, Y.; Xia, J. a.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y.; Song, J.; Wang, S.; Chao, Y.; Yang, Z.; Xu, J.; Zhou, X.; Chen, D.; Xiong, W.; Xu, L.; Zhou, F.; Jiang, J.; Bai, C.; Zheng, J.; Song, Y., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Internal Medicine* **2020**, 180 (7), 934-943. DOI: 10.1001/jamainternmed.2020.0994.
35. Ye, Q.; Wang, B.; Mao, J., The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *Journal of Infection* **2020**, 80 (6), 607-613. DOI: 10.1016/j.jinf.2020.03.037.
36. Smyk, W.; Janik, M. K.; Portincasa, P.; Milkiewicz, P.; Lammert, F.; Krawczyk, M., COVID-19: focus on the lungs but do not forget the gastrointestinal tract. *European Journal of Clinical Investigation* **2020**, 50, e13276. DOI: 10.1111/eci.13276.
37. Kampf, G.; Todt, D.; Pfaender, S.; Steinmann, E., Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. *Journal of Hospital Infection* **2020**, 104 (3), 246-251. DOI: 10.1016/j.jhin.2020.01.022.
38. Abd El-Aziz, T. M.; Stockand, J. D., Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. *Infection, Genetics and Evolution* **2020**, 83 (September), 104327. DOI: 10.1016/j.meegid.2020.104327.
39. Liu, B. M.; Yang, Q. Q.; Zhao, L. Y.; Xie, W.; Si, X. Y., Epidemiological characteristics of COVID-19 patients in convalescence period. *Epidemiol Infect* **2020**, 148, e108. DOI: 10.1017/S0950268820001181.
40. Sheervalilou, R.; Shirvaliloo, M.; Dadashzadeh, N.; Shirvalilou, S.; Shahraki, O.; Pilehvar-Soltanahmadi, Y.; Ghaznavi, H.; Khoei, S.; Nazarlou, Z., COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease. *Journal of Cellular Physiology* **2020**, 235 (12), 8873–8924. DOI: 10.1002/jcp.29735.

41. Wölfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M. A.; Niemeyer, D.; Jones, T. C.; Vollmar, P.; Rothe, C.; Hoelscher, M.; Bleicker, T.; Brünink, S.; Schneider, J.; Ehmann, R.; Zwirgmaier, K.; Drosten, C.; Wendtner, C., Virological assessment of hospitalized patients with COVID-2019. *Nature* **2020**, *581* (7809), 465-469. DOI: 10.1038/s41586-020-2196-x.
42. Centers for Disease Control and Prevention; National Center for Immunization and Respiratory Diseases (NCIRD) Division of Viral Diseases. SARS-CoV-2 variant classifications and definitions *Coronavirus Disease 2019 (COVID-19)* [Online], August 17, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html> (accessed August 20, 2021).
43. Hacisuleyman, E.; Hale, C.; Saito, Y.; Blachere, N. E.; Bergh, M.; Conlon, E. G.; Schaefer-Babajew, D. J.; DaSilva, J.; Muecksch, F.; Gaebler, C.; Landon, R.; Nussenzweig, M. C.; Hatzioannou, T.; Bieniasz, P. D.; Darnell, R. B., Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *New England Journal of Medicine* **2021**, *384* (2), 2212-2218. DOI: 10.1056/NEJMoa2105000.
44. Khateeb, J.; Li, Y.; Zhang, H., Emerging SARS-CoV-2 variants of concern and potential intervention approaches. *Critical Care* **2021**, *25* (1), 24. DOI: 10.1186/s13054-021-03662-x.
45. Simmonds, P.; Griffin, D. E., Pervasive RNA Secondary Structure in the Genomes of SARS-CoV-2 and Other Coronaviruses. *mBio* **2020**, *11* (6), e01661-20. DOI: 10.1128/mBio.01661-20.
46. V'kovski, P.; Kratzel, A.; Steiner, S.; Stalder, H.; Thiel, V., Coronavirus biology and replication: Implications for SARS-CoV-2. *Nature Reviews Microbiology* **2021**, *19* (3), 155-170. DOI: 10.1038/s41579-020-00468-6.
47. Thoms, M.; Buschauer, R.; Ameisemeier, M.; Koepke, L.; Denk, T.; Hirschenberger, M.; Kratzat, H.; Hayn, M.; Mackers-Kiani, T.; Cheng, J.; Straub, J. H.; Stürzel, C. M.; Fröhlich, T.; Berninghausen, O.; Becker, T.; Kirchhoff, F.; Sparrer, K. M. J.; Beckmann, R., Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. *Science* **2020**, *369* (6508), 1249-1253. DOI: 10.1126/science.abc8665.
48. Krokan, H. E.; Kauri, B.; Slupphaug, G.; Drablos, F., Ch. 2: The Earth, life, and genomic uracil. In *Genomic uracil: Evolution, biology, immunology and disease*, Slupphaug, G.; Krokan, H. E., Eds. World Scientific: New Jersey, 2018.
49. Di Gioacchino, A.; Šulc, P.; Komarova, A. V.; Greenbaum, B. D.; Monasson, R.; Cocco, S., The Heterogeneous landscape and early evolution of pathogen-associated CpG dinucleotides in SARS-CoV-2. *Molecular Biology and Evolution* **2021**, *38* (6), 2428-2445. DOI: 10.1093/molbev/msab036.
50. Bartas, M.; Brázda, V.; Bohálová, N.; Cantara, A.; Volná, A.; Stachurová, T.; Malachová, K.; Jagelská, E. B.; Porubiaková, O.; Červen, J.; Pečinka, P., In-depth bioinformatic analyses of *Nidovirales* including human SARS-CoV-2, SARS-CoV, MERS-CoV viruses suggest important roles of non-canonical nucleic acid structures in their lifecycles. *Frontiers in Microbiology* **2020**, *11*, 1583. DOI: 10.3389/fmicb.2020.01583.

51. Kelly, J. A.; Olson, A. N.; Neupane, K.; Munshi, S.; San Emeterio, J.; Pollack, L.; Woodside, M. T.; Dinman, J. D., Structural and functional conservation of the programmed -1 ribosomal frameshift signal of SARS coronavirus 2 (SARS-CoV-2). *Journal of Biological Chemistry* **2020**, 295 (31), 10741-10748. DOI: 10.1074/jbc.AC120.013449.
52. Choudhry, N.; Zhao, X.; Xu, D.; Zanin, M.; Chen, W.; Yang, Z.; Chen, J., Chinese therapeutic strategy for fighting COVID-19 and potential small-molecule inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Journal of Medicinal Chemistry* **2020**, 63 (22), 13205-13227. DOI: 10.1021/acs.jmedchem.0c00626.
53. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q., Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* **2020**, 367 (6485), 1444-1448. DOI: 10.1126/science.abb2762.
54. Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **2020**, 367 (6483), 1260-1263. DOI: 10.1126/science.abb2507.
55. Bergmann, C. C.; Silverman, R. H., COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. *Cleveland Clinic Journal of Medicine* **2020**, 87 (6), 321-327. DOI: 10.3949/ccjm.87a.20047.
56. Fehr, A. R.; Perlman, S., Coronaviruses: An overview of their replication and pathogenesis. In *Coronaviruses: Methods and Protocols. Methods in Molecular Biology*, Maier, H. J.; Bickerton, E.; Britton, P., Eds. Humana Press: New York, 2015; Vol. 1282, pp 1-23. DOI: 10.1007/978-1-4939-2438-7_1.
57. Finkel, Y.; Mizrahi, O.; Nachshon, A.; Weingarten-Gabbay, S.; Morgenstern, D.; Yahalom-Ronen, Y.; Tamir, H.; Adicman, H.; Stein, D.; Israeli, O.; Beth-Din, A.; Melamed, S.; Weiss, S.; Israely, T.; Paran, N.; Schwartz, M.; Stern-Ginossar, N., The coding capacity of SARS-CoV-2. *Nature* **2021**, 589 (7840), 125-130. DOI: 10.1038/s41586-020-2739-1.
58. Ogando, N. S.; Zerekenhoven-Dobbe, J. C.; Meer, Y. v. d.; Bredenbeek, P. J.; Posthuma, C. C.; Snijder, E. J.; Colledge, T., The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2. *Journal of Virology* **2020**, 94 (23), e01246-20. DOI: 10.1128/JVI.01246-20.
59. Satarker, S.; Nampoothiri, M., Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. *Archives of Medical Research* **2020**, 51 (6), 482-491. DOI: 10.1016/j.arcmed.2020.05.012.
60. Budzylowicz, C. J.; Wilczynski, S. P.; Weiss, S. R., Three intergenic regions of coronavirus mouse hepatitis virus strain A59 genome RNA contain a common nucleotide sequence that is homologous to the 3' end of the viral mRNA leader sequence. *Journal of virology* **1985**, 53 (3), 834-840. DOI: 10.1128/JVI.53.3.834-840.1985.
61. Sawicki, S. G.; Sawicki, D. L., Coronavirus minus-strand RNA synthesis and effect of cycloheximide on coronavirus RNA synthesis. *Journal of virology* **1986**, 57 (1), 328-334. DOI: 10.1128/JVI.57.1.328-334.1986.

62. Viswanathan, T.; Arya, S.; Chan, S.-H.; Qi, S.; Dai, N.; Misra, A.; Park, J.-G.; Oladunni, F.; Kovalskyy, D.; Hromas, R. A.; Martinez-Sobrido, L.; Gupta, Y. K., Structural basis of RNA cap modification by SARS-CoV-2. *Nature Communications* **2020**, *11* (1), 3718. DOI: 10.1038/s41467-020-17496-8.
63. Collier, A. M.; Lyytinen, O. L.; Guo, Y. R.; Toh, Y.; Poranen, M. M.; Tao, Y. J., Initiation of RNA Polymerization and Polymerase Encapsidation by a Small dsRNA Virus. *PLoS Pathogens* **2016**, *12* (4), e1005523. DOI: 10.1371/journal.ppat.1005523.
64. Kadam, S. B.; Sukhramani, G. S.; Bishnoi, P.; Pable, A. A.; Barvkar, V. T., SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. *Journal of Basic Microbiology* **2021**, *61* (3), 180-202. DOI: 10.1002/jobm.202000537.
65. National Center for Biotechnology Information; National Library of Medicine; National Institutes of Health SARS-CoV-2 proteins – NCBI Datasets. <https://www.ncbi.nlm.nih.gov/datasets/coronavirus/proteins/> (accessed March 2021).
66. Rabaan, A. A.; Al-Ahmed, S. H.; Haque, S.; Sah, R.; Tiwari, R.; Malik, Y. S.; Dhama, K.; Yatoo, M. I.; Bonilla-Aldana, D. K.; Rodriguez-Morales A. J., SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview *Le infezioni in medicina* [Online], 2020, p. 174-184. https://www.infezmed.it/index.php/article?Anno=2020&numero=2&ArticoloDaVisualizzare=Vol_28_2_2020_174 (accessed June 2020).
67. Chasman, D. I., *Protein structure: Determination, analysis and applications for drug discovery*. Marcel Dekker: New York, 2003.
68. Ilari, A.; Savino, C., Protein structure determination by X-ray crystallography. In *Bioinformatics: Data, Sequence Analysis and Evolution*, Keith, J. M., Ed. Humana Press: Totowa, NJ, 2008; pp 63-87. DOI: 10.1007/978-1-60327-159-2_3.
69. Ramesh, V.; Baslé, A.; Lewis, R. J., Principles and practice in macromolecular X-ray crystallography. In *Biomolecular and Bioanalytical Techniques: Theory, Methodology and Applications*, Ramesh, V., Ed. Wiley: Hoboken, NJ, 2019; pp 385-419. DOI: 10.1002/9781119480971.ch16.
70. Yang, Y.-J.; Wang, S.; Zhang, B.; Shen, H.-B., Resolution measurement from a single reconstructed cryo-em density map with multiscale spectral analysis. *Journal of Chemical Information and Modeling* **2018**, *58* (6), 1303-1311. DOI: 10.1021/acs.jcim.8b00149.
71. Bartesaghi, A.; Matthies, D.; Banerjee, S.; Merk, A.; Subramaniam, S., Structure of β -galactosidase at 3.2-Å resolution obtained by cryo-electron microscopy. *Proceedings of the National Academy of Sciences* **2014**, *111* (32), 11709-11714. DOI: 10.1073/pnas.1402809111.
72. Howes, L., The race to reveal the new coronavirus's structure. *C&EN Global Enterprise* **2020**, *98* (17), 16-19. DOI: 10.1021/cen-09817-feature1.
73. Steven, A.; Belnap, D., Electron microscopy and image processing: An essential tool for structural analysis of macromolecules. *Current Protocols in Protein Science* **2005**, *42* (1), 17.2.1-17.2.39. DOI: 10.1002/0471140864.ps1702s42.

74. Cross, R.; Howes, L.; Satyanarayana, M., 8 tools that helped us tackle the coronavirus. *C&EN Global Enterprise* **2021**, 99 (3), 38-43. DOI: 10.1021/cen-09903-feature3.
75. Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K.-Y.; Wang, Q.; Zhou, H.; Yan, J.; Qi, J., Structural and functional basis of SARS-CoV-2 entry by using human ACE2. *Cell* **2020**, 181 (4), 894-904, e1-e9. DOI: 10.1016/j.cell.2020.03.045.
76. Xia, S.; Liu, M.; Wang, C.; Xu, W.; Lan, Q.; Feng, S.; Qi, F.; Bao, L.; Du, L.; Liu, S.; Qin, C.; Sun, F.; Shi, Z.; Zhu, Y.; Jiang, S.; Lu, L., Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Research* **2020**, 30 (4), 343-355. DOI: 10.1038/s41422-020-0305-x.
77. Du, L.; He, Y.; Zhou, Y.; Liu, S.; Zheng, B.-J.; Jiang, S., The spike protein of SARS-CoV — a target for vaccine and therapeutic development. *Nature Reviews Microbiology* **2009**, 7 (3), 226-236. DOI: 10.1038/nrmicro2090.
78. Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**, 26 (4), 450-452. DOI: 10.1038/s41591-020-0820-9.
79. Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N. G.; Decroly, E., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Research* **2020**, 176 (April), 104742. DOI: 10.1016/j.antiviral.2020.104742.
80. Wu, F.; Zhao, S.; Yu, B.; Chen, Y.-M.; Wang, W.; Song, Z.-G.; Hu, Y.; Tao, Z.-W.; Tian, J.-H.; Pei, Y.-Y.; Yuan, M.-L.; Zhang, Y.-L.; Dai, F.-H.; Liu, Y.; Wang, Q.-M.; Zheng, J.-J.; Xu, L.; Holmes, E. C.; Zhang, Y.-Z., A new coronavirus associated with human respiratory disease in China. *Nature* **2020**, 579 (7708), 265-269. DOI: 10.1038/s41586-020-2008-3.
81. Liu, Z.; Xiao, X.; Wei, X.; Li, J.; Yang, J.; Tan, H.; Zhu, J.; Zhang, Q.; Wu, J.; Liu, L., Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *Journal of Medical Virology* **2020**, 92 (6), 595-601. DOI: 10.1002/jmv.25720.
82. Gao, Y.; Yan, L.; Huang, Y.; Liu, F.; Zhao, Y.; Cao, L.; Wang, T.; Sun, Q.; Ming, Z.; Zhang, L.; Ge, J.; Zheng, L.; Zhang, Y.; Wang, H.; Zhu, Y.; Zhu, C.; Hu, T.; Hua, T.; Zhang, B.; Yang, X.; Li, J.; Yang, H.; Liu, Z.; Xu, W.; Guddat, L. W.; Wang, Q.; Lou, Z.; Rao, Z., Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science* **2020**, 368 (6492), 779-782. DOI: 10.1126/science.abb7498.
83. Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; Duan, Y.; Yu, J.; Wang, L.; Yang, K.; Liu, F.; Jiang, R.; Yang, X.; You, T.; Liu, X.; Yang, X.; Bai, F.; Liu, H.; Liu, X.; Guddat, L. W.; Xu, W.; Xiao, G.; Qin, C.; Shi, Z.; Jiang, H.; Rao, Z.; Yang, H., Structure of M^{pro} from SARS-CoV-2 and discovery of its inhibitors. *Nature* **2020**, 582, 289-293. DOI: 10.1038/s41586-020-2223-y.

84. Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R., Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors. *Science* **2020**, 368 (6489), 409-412. DOI: 10.1126/science.abb3405.
85. Lu, H.; Zhang, Y.; Yang, P., Advancements in mass spectrometry-based glycoproteomics and glycomics. *National Science Review* **2016**, 3 (3), 345-364. DOI: 10.1093/nsr/nww019.
86. Burda, P.; Aeby, M., The dolichol pathway of N-linked glycosylation. *Biochimica et Biophysica Acta (BBA) - General Subjects* **1999**, 1426 (2), 239-257. DOI: 10.1016/S0304-4165(98)00127-5.
87. Brooker, R. J.; Widmaier, E. P.; Graham, L. E.; Stiling, P. D., Chapter 6 - Systems Biology of Cell Organization. In *Biology*, McGraw-Hill Higher Education: Boston, 2008.
88. Arnaud, C. H., Adding the missing sugars to coronavirus protein structures. *C&EN Global Enterprise* **2020**, 98 (16), 24-25. DOI: 10.1021/cen-00815-feature2.
89. Shajahan, A.; Supekar, N. T.; Gleinich, A. S.; Aladi, P., Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. *Glycobiology* **2020**, 30 (12), 981-988. DOI: 10.1093/glycob/cwaa042.
90. Watanabe, Y.; Allen, J. D.; Wrapp, D.; McClellan, J. S.; Crispin, M., Site-specific glycan analysis of the SARS-CoV-2 spike. *Science* **2020**, 369 (6501), 330-333. DOI: 10.1126/science.abb9983.
91. Zhang, Y.; Zhao, W.; Mao, Y.; Chen, Y.; Wang, S.; Zhong, Y.; Su, T.; Gong, M.; Du, D.; Lu, X.; Cheng, J.; Yang, H., Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins. *Molecular & Cellular Proteomics* **2021**, 20, 100058. DOI: 10.1074/mcp.RA120.002295.
92. Bagdonaite, I.; Thompson, A. J.; Wang, X.; Søgaard, M.; Fougeroux, C.; Frank, M.; Diedrich, J. K.; Yates, J. R.; Calanti, A.; Vakhrushev, S. Y.; Paulson, J. C.; Wandall, H. H., Site-Specific O-Glycosylation Analysis of SARS-CoV-2 Spike Protein Produced in Insect and Human Cells. *Viruses* **2021**, 13 (4), 551. DOI: 10.3390/v13040551.
93. Imperiali, B.; O'Connor, S. E., Effect of N-linked glycosylation on glycopeptide and glycoprotein structure. *Current Opinion in Chemical Biology* **1999**, 3 (6), 643-649. DOI: 10.1016/S1367-5931(99)00021-6.
94. Hioe, C. E.; Jan, M.; Feyznejhad, R.; Itri, V.; Liu, X.; Upadhyay, C. HIV-1 envelope glycan composition influences virus-host interaction *The Journal of Immunology* [Online], 2019, p. 197.17. http://www.jimmunol.org/content/202/1_Supplement/197.17.abstract (accessed June 2020).
95. Hioe, C. E.; Jan, M.; Upadhyay, C. HIV-1 envelope glycan composition is a key determinant of efficient virus transmission via DC-SIGN and resistance to antibodies and inhibitory lectins *The Journal of Immunology* [Online], 2020, p. 247.8. http://www.jimmunol.org/content/204/1_Supplement/247.8.abstract (accessed June 2020).

96. Howes, L., COVID-19: What you need to know about SARS-CoV-2 variants. *C&EN Global Enterprise* **2021**, 99 (20), 18-19. DOI: 10.1021/cen-09920-feature1.
97. Alam, I.; Kamau, A. A.; Kulmanov, M.; Jaremko, Ł.; Arold, S. T.; Pain, A.; Gojobori, T.; Duarte, C. M., Functional pangenome analysis shows key features of E protein are preserved in SARS and SARS-CoV-2. *Frontiers in Cellular and Infection Microbiology* **2020**, 10, 405. DOI: 10.3389/fcimb.2020.00405.
98. Wilson, L.; McKinlay, C.; Gage, P.; Ewart, G., SARS coronavirus E protein forms cation-selective ion channels. *Virology* **2004**, 330 (1), 322-331. DOI: 10.1016/j.virol.2004.09.033.
99. Nieva, J. L.; Madan, V.; Carrasco, L., Viroporins: structure and biological functions. *Nature Reviews Microbiology* **2012**, 10 (8), 563-574. DOI: 10.1038/nrmicro2820.
100. Zhang, R.; Wang, K.; Lv, W.; Yu, W.; Xie, S.; Xu, K.; Schwarz, W.; Xiong, S.; Sun, B., The ORF4a protein of human coronavirus 229E functions as a viroporin that regulates viral production. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **2014**, 1838 (4), 1088-1095. DOI: 10.1016/j.bbamem.2013.07.025.
101. Pham, T.; Perry, J. L.; Dosey, T. L.; Delcour, A. H.; Hyser, J. M., The rotavirus NSP4 viroporin domain is a calcium-conducting ion channel. *Scientific Reports* **2017**, 7, 43487. DOI: 10.1038/srep43487.
102. Duart, G.; García-Murria, M. J.; Grau, B.; Acosta-Cáceres, J. M.; Martínez-Gil, L.; Mingarro, I., SARS-CoV-2 envelope protein topology in eukaryotic membranes. *Open Biol* **2020**, 10 (9), 200209. DOI: 10.1098/rsob.200209.
103. Liao, Y.; Tam, J. P.; Liu, D. X., Viroporin activity of SARS-CoV E protein. *Adv Exp Med Biol* **2006**, 581, 199-202. DOI: 10.1007/978-0-387-33012-9_34.
104. Fung, T. S.; Liu, D. X., Coronavirus infection, ER stress, apoptosis and innate immunity. *Frontiers in Microbiology* **2014**, 5, 296. DOI: 10.3389/fmicb.2014.00296.
105. Wu, Q.; Zhang, Y.; Lü, H.; Wang, J.; He, X.; Liu, Y.; Ye, C.; Lin, W.; Hu, J.; Ji, J.; Xu, J.; Ye, J.; Hu, Y.; Chen, W.; Li, S.; Wang, J.; Wang, J.; Bi, S.; Yang, H., The E protein is a multifunctional membrane protein of SARS-CoV. *Genomics, Proteomics & Bioinformatics* **2003**, 1 (2), 131-144. DOI: 10.1016/S1672-0229(03)01017-9.
106. Bianchi, M.; Benvenuto, D.; Giovanetti, M.; Angeletti, S.; Ciccozzi, M.; Pascarella, S., SARS-CoV-2 envelope and membrane proteins: Structural differences linked to virus characteristics? *BioMed Research International* **2020**, 2020, 4389089. DOI: 10.1155/2020/4389089.
107. de Haan, C. A. M.; Vennema, H.; Rottier, P. J. M., Assembly of the coronavirus envelope: homotypic interactions between the M proteins. *Journal of Virology* **2000**, 74 (11), 4967-4978. DOI: 10.1128/JVI.74.11.4967-4978.2000.

108. Lan, J.; Ge, J.; Yu, J.; Shan, S.; Zhou, H.; Fan, S.; Zhang, Q.; Shi, X.; Wang, Q.; Zhang, L.; Wang, X., Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* **2020**, 581 (7807), 215-220. DOI: 10.1038/s41586-020-2180-5.
109. Hu, Y.; Wen, J.; Tang, L.; Zhang, H.; Zhang, X.; Li, Y.; Wang, J.; Han, Y.; Li, G.; Shi, J.; Tian, X.; Jiang, F.; Zhao, X.; Wang, J.; Liu, S.; Zeng, C.; Wang, J.; Yang, H., The M protein of SARS-CoV: Basic structural and immunological properties. *Genomics, Proteomics & Bioinformatics* **2003**, 1 (2), 118-130. DOI: 10.1016/S1672-0229(03)01016-7.
110. Arndt, A. L.; Larson, B. J.; Hogue, B. G., A conserved domain in the coronavirus membrane protein tail is important for virus assembly. *Journal of Virology* **2010**, 84 (21), 11418-11428. DOI: 10.1128/JVI.01131-10.
111. McBride, R.; Van Zyl, M.; Fielding, B. C., The coronavirus nucleocapsid Is a multifunctional protein. *Viruses* **2014**, 6 (8), 2991-3018. DOI: 10.3390/v6082991.
112. Surjit, M.; Lal, S. K., The SARS-CoV nucleocapsid protein: A protein with multifarious activities. *Infection, Genetics and Evolution* **2008**, 8 (4), 397-405. DOI: 10.1016/j.meegid.2007.07.004.
113. Kang, S.; Yang, M.; Hong, Z.; Zhang, L.; Huang, Z.; Chen, X.; He, S.; Zhou, Z.; Zhou, Z.; Chen, Q.; Yan, Y.; Zhang, C.; Shan, H.; Chen, S., Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. *Acta Pharmaceutica Sinica B* **2020**, 10 (7), 1225-1238. DOI: 10.1016/j.apsb.2020.04.009.
114. Vandelli, A.; Monti, M.; Milanetti, E.; Armaos, A.; Rupert, J.; Zacco, E.; Bechara, E.; Delli Ponti, R.; Tartaglia, Gian G., Structural analysis of SARS-CoV-2 genome and predictions of the human interactome. *Nucleic Acids Research* **2020**, 48 (20), 11270-11283. DOI: 10.1093/nar/gkaa864.
115. Schubert, K.; Karousis, E. D.; Jomaa, A.; Scaiola, A.; Echeverria, B.; Gurzeler, L.-A.; Leibundgut, M.; Thiel, V.; Möhlmann, O.; Ban, N., SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. *Nature Structural & Molecular Biology* **2020**, 27 (10), 959-966. DOI: 10.1038/s41594-020-0511-8.
116. Cornillez-Ty, C.; Liao, L.; Yates, J. R.; Kuhn, P.; Buchmeier, M. J., Severe Acute Respiratory Syndrome Coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling. *Journal of Virology* **2009**, 83 (19), 10314-10318. DOI: 10.1128/JVI.00842-09.
117. Lei, J.; Kusov, Y.; Hilgenfeld, R., Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. *Antiviral Research* **2018**, 149 (January), 58-74. DOI: 10.1016/j.antiviral.2017.11.001.
118. Li, G.; De Clercq, E., Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nature Reviews Drug Discovery* **2020**, 19 (3), 149-150. DOI: 10.1038/d41573-020-00016-0.

119. Claverie, J.-M., A putative role of de-mono-ADP-ribosylation of STAT1 by the SARS-CoV-2 nsp3 protein in the cytokine storm syndrome of COVID-19. *Viruses* **2020**, *12* (6), 646. DOI: 10.3390/v12060646.
120. Lehmann, K. C.; Gulyaeva, A.; Zevenhoven-Dobbe, J. C.; Janssen, George M. C.; Ruben, M.; Overkleeft, H. S.; van Veelen, P. A.; Samborskiy, Dmitry V.; Kravchenko, A. A.; Leontovich, A. M.; Sidorov, I. A.; Snijder, E. J.; Posthuma, C. C.; Gorbalenya, A. E., Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. *Nucleic Acids Research* **2015**, *43* (17), 8416-8434. DOI: 10.1093/nar/gkv838.
121. Yin, W.; Mao, C.; Luan, X.; Shen, D.-D.; Shen, Q.; Su, H.; Wang, X.; Zhou, F.; Zhao, W.; Gao, M.; Chang, S.; Xie, Y.-C.; Tian, G.; Jiang, H.-W.; Tao, S.-C.; Shen, J.; Jiang, Y.; Jiang, H.; Xu, Y.; Zhang, S.; Zhang, Y.; Xu, H. E., Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science* **2020**, *368* (6498), 1499-1504. DOI: 10.1126/science.abc1560.
122. Howes, L., Another coronavirus drug target imaged. *C&EN Global Enterprise* **2020**, *98* (15), 4. DOI: 10.1021/cen-09815-scicon1.
123. Kirchdoerfer, R. N.; Ward, A. B., Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. *Nature Communications* **2019**, *10*, 2342. DOI: 10.1038/s41467-019-10280-3.
124. Ma, Y.; Wu, L.; Shaw, N.; Gao, Y.; Wang, J.; Sun, Y.; Lou, Z.; Yan, L.; Zhang, R.; Rao, Z., Structural basis and functional analysis of the SARS coronavirus nsp14–nsp10 complex. *Proceedings of the National Academy of Sciences* **2015**, *112* (30), 9436-9441. DOI: 10.1073/pnas.1508686112.
125. Kim, Y.; Jedrzejczak, R.; Maltseva, N. I.; Wilamowski, M.; Endres, M.; Godzik, A.; Michalska, K.; Joachimiak, A., Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. *Protein Science* **2020**, *29* (7), 1596-1605. DOI: 10.1002/pro.3873.
126. Rosas-Lemus, M.; Mirasov, G.; Shuvalova, L.; Inniss, N. L.; Kiryukhina, O.; Wiersum, G.; Kim, Y.; Jedrzejczak, R.; Maltseva, N. I.; Endres, M.; Jaroszewski, L.; Godzik, A.; Joachimiak, A.; Satchell, K. J. F., The crystal structure of nsp10–nsp16 heterodimer from SARS-CoV-2 in complex with S-adenosylmethionine. *bioRxiv* **2020**, (Preprint), 047498. DOI: 10.1101/2020.04.17.047498.
127. Konkolova, E.; Klima, M.; Nencka, R.; Boura, E., Structural analysis of the putative SARS-CoV-2 primase complex. *Journal of Structural Biology* **2020**, *211* (2), 107548. DOI: 10.1016/j.jsb.2020.107548.
128. Jia, Z.; Yan, L.; Ren, Z.; Wu, L.; Wang, J.; Guo, J.; Zheng, L.; Ming, Z.; Zhang, L.; Lou, Z.; Rao, Z., Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis. *Nucleic Acids Research* **2019**, *47* (12), 6538-6550. DOI: 10.1093/nar/gkz409.

129. Frieman, M.; Yount, B.; Agnihothram, S.; Page, C.; Donaldson, E.; Roberts, A.; Vogel, L.; Woodruff, B.; Scorpio, D.; Subbarao, K.; Baric, R. S., Molecular determinants of Severe Acute Respiratory Syndrome Coronavirus pathogenesis and virulence in young and aged mouse models of human disease. *Journal of Virology* **2012**, 86 (2), 884-897. DOI: 10.1128/JVI.05957-11.
130. de Haan, C. A. M.; Kuo, L.; Masters, P. S.; Vennema, H.; Rottier, P. J. M., Coronavirus particle assembly: Primary structure requirements of the membrane protein. *Journal of Virology* **1998**, 72 (8), 6838-6850. DOI: 10.1128/JVI.72.8.6838-6850.1998.
131. Wu, A.; Peng, Y.; Huang, B.; Ding, X.; Wang, X.; Niu, P.; Meng, J.; Zhu, Z.; Zhang, Z.; Wang, J.; Sheng, J.; Quan, L.; Xia, Z.; Tan, W.; Cheng, G.; Jiang, T., Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. *Cell Host & Microbe* **2020**, 27 (3), 325-328. DOI: 10.1016/j.chom.2020.02.001.
132. Narayanan, K.; Huang, C.; Makino, S., SARS coronavirus accessory proteins. *Virus Research* **2008**, 133 (1), 113-121. DOI: 10.1016/j.virusres.2007.10.009.
133. Das, A.; Bhattacharya, M.; Roy, R.; P.Ghosh; N Mondal; Das, T.; B.K.Behera; Patra, B. C.; Acharya, S., Genetic diversity and structural characterization of spike glycoprotein of newly emerged SARS-CoV-2. *Research Square* **2020**, (Preprint), 1PR167372 DOI: 10.21203/rs.3.rs-31235/v1.
134. Yang, J.; Yan, R.; Roy, A.; Xu, D.; Hoischon, J.; Zhang, Y., The I-TASSER suite: Protein structure and function prediction. *Nature Methods* **2015**, 12 (1), 7-8. DOI: 10.1038/nmeth.3213.
135. Lukassen, S.; Chua, R. L.; Truffer, T.; Kahn, N. C.; Schneider, M. A.; Muley, T.; Winter, H.; Meister, M.; Veith, C.; Boots, A. W.; Hennig, B. P.; Kreuter, M.; Conrad, C.; Eils, R., SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. *The EMBO Journal* **2020**, 39 (10), e105114. DOI: 10.15252/embj.20105114.
136. Ziegler, C. G. K.; Anon, S. J.; Nyquist, S. K.; Mbano, I. M.; Miao, V. N.; Tzouanas, C. N.; Cao, Y.; Yousif, A. S.; Balle, J.; Hauser, B. M.; Feldman, J.; Muus, C.; Wadsworth, M. H.; Kazer, S. W.; Hughes, T. K.; Dorn, B.; Gatter, G. J.; Vukovic, M.; Taliaferro, F.; Mead, B. E.; Guo, Z.; Wang, J. P.; Gras, D.; Pleasant, M.; Ansari, M.; Angelidis, I.; Adler, H.; Sucre, J. M. S.; Taylor, C. J.; Lin, B.; Waghray, A.; Mitsialis, V.; Dwyer, D. F.; Buchheit, K. M.; Boyce, J. A.; Barrett, N. A.; Laidlaw, T. M.; Carroll, S. L.; Colonna, L.; Tkachev, V.; Peterson, C. W.; Yu, A.; Zheng, H. B.; Gideon, H. P.; Winchell, C. G.; Lin, P. L.; Bingle, C. D.; Snapper, S. B.; Kropski, J. A.; Theis, F. J.; Schiller, H. B.; Zaragosi, L.-E.; Barbry, P.; Leslie, A.; Kiem, H.-P.; Flynn, J. L.; Fortune, S. M.; Berger, B.; Finberg, R. W.; Kean, L. S.; Garber, M.; Schmidt, A. G.; Lingwood, D.; Shalek, A. K.; Ordovas-Montanes, J.; Banovich, N.; Barbry, P.; Brazma, A.; Desai, T.; Duong, T. E.; Eickelberg, O.; Falk, C.; Farzan, M.; Glass, I.; Haniffa, M.; Horvath, P.; Hung, D.; Kaminski, N.; Krasnow, M.; Kropski, J. A.; Kuhnemund, M.; Lafyatis, R.; Lee, H.; Leroy, S.; Linnarson, S.; Lundeborg, J.; Meyer, K.; Misharin, A.; Nawijn, M.; Nikolic, M. Z.; Ordovas-Montanes, J.; Pe'er, D.; Powell, J.; Quake, S.; Rajagopal, J.; Tata, P. R.; Rawlins, E. L.; Regev, A.; Reyfman, P. A.; Rojas, M.; Rosen, O.; Saeb-Parsy, K.; Samakovlis, C.; Schiller, H.; Schultze, J. L.; Seibold, M. A.; Shalek, A. K.; Shepherd, D.; Spence, J.; Spira, A.; Sun, X.; Teichmann, S.; Theis, F.; Tsankov, A.; van den Berge, M.; von Papen, M.; Whitsett, J.; Xavier, R.; Xu, Y.; Zaragosi, L.-E.; Zhang, K., SARS-CoV-2 receptor ACE2 Is an interferon-stimulated gene in human airway

epithelial cells and is detected in specific cell subsets across tissues. *Cell* **2020**, 181 (5), 1016-1035, e1-e19. DOI: 10.1016/j.cell.2020.04.035.

137. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T. S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; Müller, M. A.; Drosten, C.; Pöhlmann, S., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* **2020**, 181 (2), 271-280, e1-e8. DOI: 10.1016/j.cell.2020.02.052.

138. Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; Zhao, Y.; Liu, P.; Liang, L.; Cui, P.; Wang, J.; Zhang, X.; Guan, Y.; Tan, W.; Wu, G.; Chen, H.; Bu, Z., Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. *Science* **2020**, 368 (6494), 1016-1020. DOI: 10.1126/science.abb7015.

139. Hussain, M.; Jabeen, N.; Raza, F.; Shabbir, S.; Baig, A. A.; Amanullah, A.; Aziz, B., Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. *Journal of Medical Virology* **2020**, 92 (9), 1580-1586. DOI: 10.1002/jmv.25832.

140. Hussain, M.; Jabeen, N.; Amanullah, A.; Baig, A. A.; Aziz, B.; Shabbir, S.; Raza, F.; Uddin, N., Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions. *AIMS Microbiol* **2020**, 6 (3), 350-360. DOI: 10.3934/microbiol.2020021.

141. Hoffmann, M.; Kleine-Weber, H.; Pöhlmann, S., A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. *Molecular Cell* **2020**, 78 (4), 779-784, e1-e5. DOI: 10.1016/j.molcel.2020.04.022.

142. Sungnak, W.; Huang, N.; Bécavin, C.; Berg, M.; Queen, R.; Litvinukova, M.; Talavera-López, C.; Maatz, H.; Reichart, D.; Sampaziotis, F.; Worlock, K. B.; Yoshida, M.; Barnes, J. L.; Banovich, N. E.; Barbry, P.; Brazner, A.; Collin, J.; Desai, T. J.; Duong, T. E.; Eickelberg, O.; Falk, C.; Farzan, M.; Glass, I.; Gupta, R. K.; Haniffa, M.; Horvath, P.; Hubner, N.; Hung, D.; Kaminski, N.; Krasnow, M.; Kroppe, J. A.; Kuhnemund, M.; Lako, M.; Lee, H.; Leroy, S.; Linnarson, S.; Lundberg, J.; Meyer, K. B.; Miao, Z.; Misharin, A. V.; Nawijn, M. C.; Nikolic, M. Z.; Nosedá, M.; Ordoñez-Monreal, J.; Oudit, G. Y.; Pe'er, D.; Powell, J.; Quake, S.; Rajagopal, J.; Tata, P. R.; Rawlins, J. L.; Regev, A.; Reyfman, P. A.; Rozenblatt-Rosen, O.; Saeb-Parsy, K.; Samakovlis, C.; Schiller, H. B.; Schultze, J. L.; Seibold, M. A.; Seidman, C. E.; Seidman, J. G.; Shalek, A. K.; Shepherd, D.; Spence, J.; Spira, A.; Sun, X.; Teichmann, S. A.; Theis, F. J.; Tsankov, A. M.; Vallier, L.; van den Berge, M.; Whitsett, J.; Xavier, R.; Xu, Y.; Zaragosi, L.-E.; Zerti, D.; Zhang, H.; Zhang, K.; Rojas, M.; Figueiredo, F.; HCA Lung Biological Network, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nature Medicine* **2020**, 26 (5), 681-687. DOI: 10.1038/s41591-020-0868-6.

143. Lam, S. D.; Bordin, N.; Waman, V. P.; Scholes, H. M.; Ashford, P.; Sen, N.; van Dorp, L.; Rauer, C.; Dawson, N. L.; Pang, C. S. M.; Abbasian, M.; Sillitoe, I.; Edwards, S. J. L.; Fraternali, F.; Lees, J. G.; Santini, J. M.; Orengo, C. A., SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals. *Scientific Reports* **2020**, 10 (1), 16471. DOI: 10.1038/s41598-020-71936-5.

144. Chowdhury, R.; Boorla, V. S.; Maranas, C. D., Computational biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and

implications for infectivity. *Computational and Structural Biotechnology Journal* **2020**, 18, 2573-2582. DOI: 10.1016/j.csbj.2020.09.019.

145. Laurini, E.; Marson, D.; Aulic, S.; Fermeglia, M.; Priol, S., Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. *ACS Nano* **2020**, 14 (9), 11821-11830. DOI: 10.1021/acsnano.0c04674.

146. Wang, Y.; Liu, M.; Gao, J., Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. *Proceedings of the National Academy of Sciences* **2020**, 117 (25), 13967-13974. DOI: 10.1073/pnas.2008209117.

147. Hatmal, M. M.; Alshaer, W.; Al-Hatamleh, M. A. I.; Hatmal, M.; Smadi, O.; Taha, M. O.; Oweida, A. J.; Boer, J. C.; Mohamud, R.; Plebanski, M., Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. *Cells* **2020**, 9 (12), 2638. DOI: 10.3390/cells9122638.

148. Baxter, B. D.; Larson, E. D.; Merle, L.; Feinstein, P.; Polese, A. G.; Bubak, A. N.; Niemeyer, C. S.; Hassell, J.; Shepherd, D.; Ramakrishnan, V. R.; Nagel, M. A.; Restrepo, D., Transcriptional profiling reveals potential involvement of microvillous TRPM5-expressing cells in viral infection of the olfactory epithelium. *BMC Genomics* **2021**, 22 (1), 224. DOI: 10.1186/s12864-021-07528-y.

149. Hikmet, F.; Méar, L.; Edvinsson, Å.; Micera, P.; Uhlén, M.; Lindskog, C., The protein expression profile of ACE2 in human tissues. *Molecular Systems Biology* **2020**, 16 (7), e9610. DOI: 10.15252/msb.20209610.

150. Guo, J.; Huang, Z.; Lin, L.; Lv, C., Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Journal of the American Heart Association* **2020**, 9 (7), e016219. DOI: doi:10.1161/JAHA.120.016219.

151. Xu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q., High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *International Journal of Oral Science* **2020**, 12 (1), 8. DOI: 10.1038/s41368-020-0074-x.

152. Zhang, Y.; Geng, X.; Tan, Y.; Li, Q.; Xu, C.; Xu, J.; Hao, L.; Zeng, Z.; Luo, X.; Liu, F.; Wang, H., New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. *Biomedicine & Pharmacotherapy* **2020**, 127 (July), 110195. DOI: 10.1016/j.biopha.2020.110195.

153. Seah, I.; Su, X.; Lingam, G., Revisiting the dangers of the coronavirus in the ophthalmology practice. *Eye (London)* **2020**, 34, 1155-1157. DOI: 10.1038/s41433-020-0790-7.

154. Wang, J.; Zhao, S.; Liu, M.; Zhao, Z.; Xu, Y.; Wang, P.; Lin, M.; Xu, Y.; Huang, B.; Zuo, X.; Chen, Z.; Bai, F.; Cui, J.; Lew, A. M.; Zhao, J.; Zhang, Y.; Luo, H.; Zhang, Y., ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism. *medRxiv* **2020**, (Preprint), 20020545. DOI: 10.1101/2020.02.05.20020545.

155. Xia, J.; Tong, J.; Liu, M.; Shen, Y.; Guo, D., Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. *Journal of Medical Virology* **2020**, 92 (6), 589-594. DOI: 10.1002/jmv.25725.
156. Xiao, F.; Tang, M.; Zheng, X.; Liu, Y.; Li, X.; Shan, H., Evidence for gastrointestinal infection of SARS-CoV-2. *Gastroenterology* **2020**, 158 (6), 1831-1833, e1-e3. DOI: 10.1053/j.gastro.2020.02.055.
157. Zhang, H.; Kang, Z.; Gong, H.; Xu, D.; Wang, J.; Li, Z.; Cui, X.; Xiao, J.; Meng, T.; Zhou, W.; Liu, J.; Xu, H., The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. *bioRxiv* **2020**, (Preprint), 927806. DOI: 10.1101/2020.01.30.927806.
158. Ding, Y.; He, L.; Zhang, Q.; Huang, Z.; Che, X.; Hou, J.; Wang, H.; Shen, H.; Qiu, L.; Li, Z.; Geng, J.; Cai, J.; Han, H.; Li, X.; Kang, W.; Weng, D.; Liang, P.; Jiang, S., Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. *The Journal of Pathology* **2004**, 203 (2), 622-630. DOI: 10.1002/path.1510.
159. Wang, N.; Shi, X.; Jiang, L.; Zhang, S.; Wang, D.; Tong, P.; Guo, D.; Fu, L.; Cui, Y.; Liu, X.; Arledge, K. C.; Chen, Y.-H.; Zhang, L.; Wang, X., Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. *Cell Research* **2013**, 23 (8), 986-993. DOI: 10.1038/cr.2013.92.
160. Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.-F.; Shi, Z.-L., A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **2020**, 579 (7798), 270-273. DOI: 10.1038/s41586-020-2012-7.
161. Brake, S. J.; Barnsley, K.; Lu, W.; McAlinden, K. D.; Eapen, M. S.; Sohal, S. S., Smoking upregulates angiotensin-converting enzyme-2 receptor: A potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). *Journal of Clinical Medicine* **2020**, 9 (3), 841. DOI: 10.3390/jcm9030841.
162. Muus, C.; Luecken, M. D.; Eraslan, G.; Waghray, A.; Heimberg, G.; Sikkema, L.; Kobayashi, Y.; Vaishnav, E. D.; Subramanian, A.; Smilie, C.; Jagadeesh, K.; Duong, E. T.; Fiskin, E.; Triglia, E. T.; Ansari, M.; Cai, P.; Lin, B.; Buchanan, J.; Chen, S.; Shu, J.; Haber, A. L.; Chung, H.; Montoro, D. T.; Adams, T.; Aliee, H.; Samuel, J.; Andrusivova, A. Z.; Angelidis, I.; Ashenberg, O.; Bassler, K.; Bécavin, C.; Benhar, I.; Bergensträhle, J.; Bergensträhle, L.; Bolt, L.; Braun, E.; Bui, L. T.; Chaffin, M.; Chichelnitskiy, E.; Chiou, J.; Conlon, T. M.; Cuoco, M. S.; Deprez, M.; Fischer, D. S.; Gillich, A.; Gould, J.; Guo, M.; Gutierrez, A. J.; Habermann, A. C.; Harvey, T.; He, P.; Hou, X.; Hu, L.; Jaiswal, A.; Jiang, P.; Kapellos, T.; Kuo, C. S.; Larsson, L.; Leney-Greene, M. A.; Lim, K.; Litviňuková, M.; Lu, J.; Ludwig, L. S.; Luo, W.; Maatz, H.; Madissoon, E.; Mamanova, L.; Manakongtreecheep, K.; Marquette, C.-H.; Mbano, I.; McAdams, A. M.; Metzger, R. J.; Nabhan, A. N.; Nyquist, S. K.; Penland, L.; Poirion, O. B.; Poli, S.; Qi, C.; Queen, R.; Reichart, D.; Rosas, I.; Schupp, J.; Sinha, R.; Sit, R. V.; Slowikowski, K.; Slyper, M.; Smith, N.; Sountoulidis, A.; Strunz, M.; Sun, D.; Talavera-López, C.; Tan, P.; Tantivit, J.; Travaglini, K. J.; Tucker, N. R.; Vernon, K.; Wadsworth, M. H.; Waldman, J.; Wang, X.; Yan, W.; Zhao, W.; Ziegler, C. G. K., Integrated analyses of single-cell atlases reveal age,

gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. *bioRxiv* **2020**, (Preprint), 049254. DOI: 10.1101/2020.04.19.049254.

163. Dandekar, A. A.; Perlman, S., Immunopathogenesis of coronavirus infections: implications for SARS. *Nature Reviews Immunology* **2005**, 5 (12), 917-927. DOI: 10.1038/nri1732.

164. Rangan, R.; Zheludev, I. N.; Hagey, R. J.; Pham, E. A.; Wayment-Steele, H. K.; Glenn, J. S.; Das, R., RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look. *RNA* **2020**, 26 (8), 937-959. DOI: 10.1261/rna.076141.120.

165. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G. F.; Tan, W., A Novel coronavirus from patients with pneumonia in China, 2019. *New England Journal of Medicine* **2020**, 382 (8), 727-733. DOI: 10.1056/NEJMoa2001017.

166. Huo, J.; Zhao, Y.; Ren, J.; Zhou, D.; Duyvesteyn, H. M. E.; Ginn, H. M.; Carrique, L.; Malinauskas, T.; Ruza, R. R.; Shah, P. N. M.; Tan, T. K.; Rajal, P.; Coombes, N.; Bewley, K. R.; Tree, J. A.; Radecke, J.; Paterson, N. G.; Supasa, P.; Mookkolsapaya, J.; Screaton, G. R.; Carroll, M.; Townsend, A.; Fry, E. E.; Owens, R. J.; Stuart, D. I., Neutralization of SARS-CoV-2 by destruction of the prefusion spike. *Cell Host & Microbe* **2020**, 28 (3), 445-454, e1-e6. DOI: 10.1016/j.chom.2020.06.010.

167. Li, W.; Moore, M. J.; Vasilieva, N.; Sui, J.; Wong, S. K.; Berne, M. A.; Somasundaran, M.; Sullivan, J. L.; Luzuriaga, K.; Greenough, T. C.; Choe, H.; Farzan, M., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* **2003**, 426 (6965), 450-454. DOI: 10.1038/nature02145.

168. Wan, Y.; Shang, J.; Graham, R.; Baric, R. S.; Li, F., Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. *Journal of Virology* **2020**, 94 (7), e00127-20. DOI: 10.1128/JVI.00127-20.

169. Zhou, Y.; Hou, Y.; Shen, J.; Huang, Y.; Martin, W.; Cheng, F., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discovery* **2020**, 6 (1), 14. DOI: 10.1038/s41421-020-0153-3.

170. Tai, W.; He, L.; Zhang, X.; Pu, J.; Voronin, D.; Jiang, S.; Zhou, Y.; Du, L., Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. *Cellular & Molecular Immunology* **2020**, 17 (6), 613-620. DOI: 10.1038/s41423-020-0400-4.

171. Vabret, N.; Britton, G. J.; Gruber, C.; Hegde, S.; Kim, J.; Kuksin, M.; Levantovsky, R.; Malle, L.; Moreira, A.; Park, M. D.; Pia, L.; Risson, E.; Saffern, M.; Salomé, B.; Esai Selvan, M.; Spindler, M. P.; Tan, J.; van der Heide, V.; Gregory, J. K.; Alexandropoulos, K.; Bhardwaj, N.; Brown, B. D.; Greenbaum, B.; Gümüş, Z. H.; Homann, D.; Horowitz, A.; Kamphorst, A. O.; Curotto de Lafaille, M. A.; Mehandru, S.; Merad, M.; Samstein, R. M.; Agrawal, M.; Aleynick, M.; Belabed, M.; Brown, M.; Casanova-Acebes, M.; Catalan, J.; Centa, M.; Charap, A.; Chan, A.; Chen, S. T.; Chung, J.; Bozkus, C. C.; Cody, E.; Cossarini, F.; Dalla, E.; Fernandez, N.; Grout, J.; Ruan, D. F.; Hamon, P.; Humblin, E.; Jha, D.; Kodysh, J.; Leader, A.; Lin, M.;

Lindblad, K.; Lozano-Ojalvo, D.; Lubitz, G.; Magen, A.; Mahmood, Z.; Martinez-Delgado, G.; Mateus-Tique, J.; Meritt, E.; Moon, C.; Noel, J.; O'Donnell, T.; Ota, M.; Plitt, T.; Pothula, V.; Redes, J.; Reyes Torres, I.; Roberto, M.; Sanchez-Paulete, A. R.; Shang, J.; Schanoski, A. S.; Suprun, M.; Tran, M.; Vaninov, N.; Wilk, C. M.; Aguirre-Ghiso, J.; Bogunovic, D.; Cho, J.; Faith, J.; Grasset, E.; Heeger, P.; Kenigsberg, E.; Krammer, F.; Laserson, U., Immunology of COVID-19: Current state of the science. *Immunity* **2020**, 52 (6), 910-941. DOI: 10.1016/j.immuni.2020.05.002.

172. Pinto, B. G. G.; Oliveira, A. E. R.; Singh, Y.; Jimenez, L.; Gonçalves, A. N. A.; Ogawa, R. L. T.; Creighton, R.; Peron, J. P. S.; Nakaya, H. I., ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. *The Journal of Infectious Diseases* **2020**, 222 (4), 556-563. DOI: 10.1093/infdis/jiaa332.

173. Rameshrad, M.; Ghafoori, M.; Mohammadpour, A. H.; Nayari, M. J. D.; Hosseinzadeh, H., A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). *Naunyn-Schmiedeberg's Archives of Pharmacology* **2020**, 393, 1137-1152. DOI: 10.1007/s00210-020-01901-6.

174. Wu, R.; Wang, L.; Kuo, H.-C. D.; Shannar, A.; Patel, R.; Chou, P. J.; Li, S.; Hudlikar, R.; Liu, X.; Liu, Z.; Poiani, G. J.; Amorosa, L.; Brunetti, L.; Korg, A.-N., An update on current therapeutic drugs treating COVID-19. *Current Pharmacology Reports* **2020**, 6, 56-70. DOI: 10.1007/s40495-020-00216-7.

175. Subramanian, K.; Nalli, A.; Senthilvelu, Jaishankar, S.; Nayak, A.; Bhat, A., Perspectives on the early quality of evidence guiding the therapeutic management of SARS-CoV-2: A systematic literature review. *Advances in Therapy* **2020**, 37 (10), 4107-4131. DOI: 10.1007/s12325-020-01460-5.

176. Uddin, M.; Mustafa, F.; Rizvi, T. A.; Loney, T.; Al Suwaidi, H.; Al-Marzouqi, A. H. H.; Kamal Eldin, A.; Alsabeeha, N.; Alriani, T. E.; Stefanini, C.; Nowotny, N.; Alsheikh-Ali, A.; Senok, A. C., SARS-CoV-2/COVID-19: Viral genomics, epidemiology, vaccines, and therapeutic interventions. *Viruses* **2020**, 12 (3), 526. DOI: 10.3390/v12050526.

177. Al-Bari, M. A. A., Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. *Pharmacology Research & Perspectives* **2017**, 5 (1), e00293. DOI: 10.1002/prp2.293.

178. Ancy, I.; Sivanandam, M.; Kumaradhas, P., Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study. *Journal of Biomolecular Structure and Dynamics* **2020**, 1-8. DOI: 10.1080/07391102.2020.1786459.

179. Gül, Ş.; Özcan, O.; Aşar, S.; Okyar, A.; Barış, İ.; Kavaklı, I. H., In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. *Journal of Biomolecular Structure and Dynamics* **2020**, 1-20. DOI: 10.1080/07391102.2020.1802346.

180. Panda, G.; Mishra, N.; Ray, A., Genetic variations and drug repurposing provides key insights into the disruption of the SARS COV2. *OSF Preprints* **2020**, (Preprint), b7y2c. DOI: 10.31219/osf.io/b7y2c.

181. Hsieh, C.-L.; Goldsmith, J. A.; Schaub, J. M.; DiVenere, A. M.; Kuo, H.-C.; Javanmardi, K.; Le, K. C.; Wrapp, D.; Lee, A. G.; Liu, Y.; Chou, C.-W.; Byrne, P. O.; Hjorth, C. K.; Johnson, N. V.; Ludes-Meyers, J.; Nguyen, A. W.; Park, J.; Wang, N.; Amengor, D.; Lavinder, J. J.; Ippolito, G. C.; Maynard, J. A.; Finkelstein, I. J.; McLellan, J. S., Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science* **2020**, 369 (6510), 1501-1505. DOI: 10.1126/science.abd0826.
182. Osman, E. E. A.; Toogood, P. L.; Neamati, N., COVID-19: Living through another pandemic. *ACS Infectious Diseases* **2020**, 6 (7), 1548-1552. DOI: 10.1021/acsinfectdis.0c00224.
183. Wadman, M.; Couzin-Frankel, J.; Kaiser, J.; Maticic, C., A rampage through the body. *Science* **2020**, 368 (6489), 356-360. DOI: 10.1126/science.368.6489.356.
184. Luytjes, W.; Sturman, L. S.; Bredenbee, P. J.; Charite, J.; van der Zeijst, B. A. M.; Horzinek, M. C.; Spaan, W. J. M., Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site. *Virology* **1987**, 161 (2), 479-487. DOI: 10.1016/0042-6822(87)90142-5.
185. Abraham, S.; Kienzle, T. E.; Lapps, W.; Brian, D. A., Deduced sequence of the bovine coronavirus spike protein and identification of the internal proteolytic cleavage site. *Virology* **1990**, 176 (1), 296-301. DOI: 10.1016/0042-6822(90)90257-R.
186. de Groot, R. J.; Luytjes, W.; Horzinek, M. C.; van der Zeijst, B. A. M.; Spaan, W. J. M.; Lenstra, J. A., Evidence for a coiled-coil structure in the spike proteins of coronaviruses. *Journal of Molecular Biology* **1987**, 190 (4), 963-966. DOI: 10.1016/0022-2836(87)90422-0.
187. Richardson, P.; Griffin, I.; Tucker, C.; Smith, D.; Oechsle, O.; Phelan, A.; Stebbing, J., Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *The Lancet* **2020**, 395 (10223), e30-e31. DOI: 10.1016/S0140-6736(20)30304-4.
188. Liu, C.; Zhou, Q.; Li, Y.; Garner, L. V.; Watkins, S. P.; Carter, L. J.; Smoot, J.; Gregg, A. C.; Daniels, A. D.; Jervey, S.; Albani, D., Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. *ACS Central Science* **2020**, 6 (3), 315-331. DOI: 10.1021/acscentsci.0c00272.
189. Sheahan, T. P.; Sims, A. C.; Zhou, S.; Graham, R. L.; Pruijssers, A. J.; Agostini, M. L.; Leist, S. R.; Schäfer, A.; Dinno, K. H.; Stevens, L. J.; Chappell, J. D.; Lu, X.; Hughes, T. M.; George, A. S.; Hill, C. S.; Montgomery, S. A.; Brown, A. J.; Bluemling, G. R.; Natchus, M. G.; Saindane, M.; Kolykhalov, A. A.; Painter, G.; Harcourt, J.; Tamin, A.; Thornburg, N. J.; Swanstrom, R.; Denison, M. R.; Baric, R. S., An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Science Translational Medicine* **2020**, 12 (541), eabb5883. DOI: 10.1126/scitranslmed.abb5883.
190. Wang, Q.; Wu, J.; Wang, H.; Gao, Y.; Liu, Q.; Mu, A.; Ji, W.; Yan, L.; Zhu, Y.; Zhu, C.; Fang, X.; Yang, X.; Huang, Y.; Gao, H.; Liu, F.; Ge, J.; Sun, Q.; Yang, X.; Xu, W.; Liu, Z.; Yang, H.; Lou, Z.; Jiang, B.; Guddat, L. W.; Gong, P.; Rao, Z., Structural basis for RNA replication by the SARS-CoV-2 polymerase. *Cell* **2020**, 182 (2), 417-428, e1-e13. DOI: 10.1016/j.cell.2020.05.034.

191. Luan, J.; Lu, Y.; Jin, X.; Zhang, L., Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. *Biochemical and Biophysical Research Communications* **2020**, 526 (1), 165-169. DOI: 10.1016/j.bbrc.2020.03.047.
192. Ortega, J. T.; Serrano, M. L.; Pujol, F. H.; Rangel, H. R., Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An *in silico* analysis. *EXCLI J* **2020**, 19, 410-417. DOI: 10.17179/excli2020-1167.
193. Amaro, R. E.; Mulholland, A. J., A community letter regarding sharing biomolecular simulation data for COVID-19. *Journal of Chemical Information and Modeling* **2020**, 60 (6), 2653-2656. DOI: 10.1021/acs.jcim.0c00319.
194. Gao, J.; Tian, Z.; Yang, X., Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *BioScience Trends* **2020**, 14 (1), 72-73. DOI: 10.5582/bst.2020.01047.
195. Kaeppler, U.; Stiefl, N.; Schiller, M.; Vicik, R.; Breuning, A.; Schmitz, W.; Rupprecht, D.; Schmuck, C.; Baumann, K.; Ziebuhr, J.; Schirmeister, T., A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. *Journal of Medicinal Chemistry* **2005**, 48 (22), 6832-6842. DOI: 10.1021/jm0501782
196. Martina, E.; Stiefl, N.; Degel, B.; Schiller, M.; Vicik, R.; Baumann, K.; Ziebuhr, J.; Schirmeister, T., Screening of electrophilic compounds yields an aziridiny peptide as new active-site directed SARS-CoV main protease inhibitor. *Bioorganic & Medicinal Chemistry Letters* **2005**, 15 (24), 5365-5369. DOI: 10.1016/j.bmcl.2005.09.012.
197. Shah, F.; Mukherjee, P.; Desai, P.; Avery, M., Computational approaches for the discovery of cysteine protease inhibitors against malaria and SARS. *Current Computer-Aided Drug Design* **2010**, 6 (1), 1-23. DOI: 10.2174/157340910790980142.
198. Muralidharan, N.; Sathivel, R.; Velmurugan, D.; Gromiha, M. M., Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. *Journal of Biomolecular Structure and Dynamics* **2020**, 1-6. DOI: 10.1080/07391102.2020.1752802.
199. Sheahan, T. P.; Sims, A. C.; Leist, S. R.; Schäfer, A.; Won, J.; Brown, A. J.; Montgomery, S. A.; Hogg, A.; Babusis, D.; Clarke, M. O.; Spahn, J. E.; Bauer, L.; Sellers, S.; Porter, D.; Feng, J. Y.; Cihlar, T.; Jordan, R.; Denison, M. R.; Baric, R. S., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nature Communications* **2020**, 11 (1), 222. DOI: 10.1038/s41467-019-13940-6.
200. Tummino, T. A.; Rezelj, V. V.; Fischer, B.; Fischer, A.; O'Meara, M. J.; Monel, B.; Vallet, T.; White, K. M.; Zhang, Z.; Alon, A.; Schadt, H.; O'Donnell, H. R.; Lyu, J.; Rosales, R.; McGovern, B. L.; Rathnasinghe, R.; Jangra, S.; Schotsaert, M.; Galarneau, J.-R.; Krogan, N. J.; Urban, L.; Shokat, K. M.; Kruse, A. C.; García-Sastre, A.; Schwartz, O.; Moretti, F.; Vignuzzi, M.; Pognan, F.; Shoichet, B. K., Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. *Science* **2021**, 373 (6554), 541-547. DOI: 10.1126/science.abi4708.

201. Chu, C. M.; Cheng, V. C. C.; Hung, I. F. N.; Wong, M. M. L.; Chan, K. H.; Chan, K. S.; Kao, R. Y. T.; Poon, L. L. M.; Wong, C. L. P.; Guan, Y.; Peiris, J. S. M.; Yuen, K. Y., Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax* **2004**, 59 (3), 252-256. DOI: 10.1136/thorax.2003.012658.
202. Agostini, M. L.; Andres, E. L.; Sims, A. C.; Graham, R. L.; Sheahan, T. P.; Lu, X.; Smith, E. C.; Case, J. B.; Feng, J. Y.; Jordan, R.; Ray, A. S.; Cihlar, T.; Siegel, D.; Mackman, R. L.; Clarke, M. O.; Baric, R. S.; Denison, M. R., Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *mBio* **2018**, 9 (2), e00221-18. DOI: 10.1128/mBio.00221-18.
203. Grein, J.; Ohmagari, N.; Shin, D.; Diaz, G.; Asperges, E.; Castagna, A.; Feldt, T.; Green, G.; Green, M. L.; Lescure, F.-X.; Nicastri, E.; Oda, R.; Yo, K.; Quiros-Roldan, E.; Studemeister, A.; Redinski, J.; Ahmed, S.; Bennett, J.; Chelliah, D.; Chen, D.; Chhabra, S.; Cohen, S. H.; Cunningham, J.; D'Arminio Monforte, A.; Ismail, S.; Kato, H.; Lapadula, G.; L'Her, E.; Maeno, T.; Majumder, S.; Massari, M.; Mora-Rillo, M.; Mutoh, Y.; Nguyen, I.; Verweij, E.; Zoufaly, A.; Osinusi, A. O.; DeZure, A.; Zhao, Y.; Zhong, L.; Chokkalingam, A.; Elboudwarej, E.; Telep, L.; Timbs, L.; Henne, I.; Sellers, S.; Cao, H.; Tan, S. K.; Wintebourne, L.; Desai, P.; Mera, R.; Gaggari, A.; Myers, R. P.; Brainard, D. M.; Childs, R.; Flannigan, T., Compassionate use of remdesivir for patients with severe COVID-19. *New England Journal of Medicine* **2020**, 382 (24), 2327-2336. DOI: 10.1056/NEJMoa2007016.
204. Jarvis, L. M., Scaling up remdesivir amid the coronavirus crisis. *C&EN Global Enterprise* **2020**, 98 (17), 23-24. DOI: 10.1021/cen-09817.feature2.
205. Eastman, R. T.; Roth, J. S.; Brimacombe, K. R.; Simeonov, A.; Shen, M.; Patnaik, S.; Hall, M. D., Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. *ACS Central Science* **2020**, 6 (5), 672-683. DOI: 10.1021/acscentsci.0c00489.
206. U.S. National Library of Medicine. Studies found for COVID-19 and inhibitors *ClinicalTrials.gov* [Online], 2020. <https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=inhibitors> (accessed June 2020).
207. Cortegiani, A.; Ippolito, G.; Ippolito, M.; Giarratano, A.; Einav, S., A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *Journal of Critical Care* **2020**, 57 (June), 279-283. DOI: 10.1016/j.jcrc.2020.03.005.
208. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Research* **2020**, 30 (3), 269-271. DOI: 10.1038/s41422-020-0282-0.
209. de Wit, E.; Feldmann, F.; Cronin, J.; Jordan, R.; Okumura, A.; Thomas, T.; Scott, D.; Cihlar, T.; Feldmann, H., Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proceedings of the National Academy of Sciences* **2020**, 117 (12), 6771-6776. DOI: 10.1073/pnas.1922083117.
210. Holshue, M. L.; DeBolt, C.; Lindquist, S.; Lofy, K. H.; Wiesman, J.; Bruce, H.; Spitters, C.; Ericson, K.; Wilkerson, S.; Tural, A.; Diaz, G.; Cohn, A.; Fox, L.; Patel, A.; Gerber, S. I.; Kim, L.; Tong, S.; Lu, X.; Lindstrom, S.; Pallansch, M. A.; Weldon, W. C.; Biggs, H. M.; Uyeki, T. M.;

Pillai, S. K., First Case of 2019 Novel Coronavirus in the United States. *New England Journal of Medicine* **2020**, 382 (10), 929-936. DOI: 10.1056/NEJMoa2001191.

211. Hendaus, M. A., Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): A simplified summary. *Journal of Biomolecular Structure and Dynamics* **2020**, 1-8. DOI: 10.1080/07391102.2020.1767691.

212. O'Day, D.; Gilead Sciences, Inc. An open letter from Daniel O'Day, Chairman & CEO, Gilead Sciences *GILEAD: Newsroom - Press Releases* [Online], June 29, 2020. <https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/an-open-letter-from-daniel-oday-chairman-ceo-gilead-sciences> (accessed July 2020).

213. Srinivas, P.; Sacha, G. L.; Koval, C., Antivirals for COVID-19. *Cleveland Clinic Journal of Medicine* **September 29, 2020**, (COVID-19 Curbside Consults). 1-5. DOI: 10.3949/ccjm.87a.ccc030.

214. U.S. Food and Drug Administration Emergency use authorization: Emergency use authorization (EUA) information, and list of all current EUAs. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization> (accessed July 2020).

215. Jarvis, L. M., Remdesivir data offer hope, with caveats. *C&EN Global Enterprise* **2020**, 98 (17), 3. DOI: 10.1021/cen-09817-leadcor.

216. Matsuoka, K., Fujifilm tests favipiravir as COVID-19 treatment. *C&EN Global Enterprise* **2020**, 98 (15), 11. DOI: 10.1021/cen-09815-buscon4.

217. Wang, Y.; Zhou, F.; Zhang, D.; Zhao, J.; Du, R.; Hu, Y.; Cheng, Z.; Gao, L.; Jin, Y.; Luo, G.; Fu, S.; Lu, Q.; Du, G.; Wang, M.; Lu, Y.; Fan, G.; Zhang, Y.; Liu, Y.; Ruan, S.; Liu, W.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C., Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. *Trials* **2020**, 21 (1), 422. DOI: 10.1186/s13063-020-04552-9.

218. Brophy, J. M., U.S. purchases world stocks of remdesivir: Why the rest of the world should be glad to be at the back of the queue. *BMJ* **2020**, 370, m2797. DOI: 10.1136/bmj.m2797.

219. Amanat, F.; Krammer, F., SARS-CoV-2 vaccines: Status report. *Immunity* **2020**, 52 (4), 583-589. DOI: 10.1016/j.immuni.2020.03.007.

220. Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y.; Shen, C.; Li, X.; Peng, L.; Huang, D.; Zhang, J.; Zhang, S.; Wang, F.; Liu, J.; Chen, L.; Chen, S.; Wang, Z.; Zhang, Z.; Cao, R.; Zhong, W.; Liu, Y.; Liu, L., Experimental treatment with favipiravir for COVID-19: An open-label control study. *Engineering (Beijing)* **2020**, 6 (10), 1192-1198. DOI: 10.1016/j.eng.2020.03.007.

221. Mullard, A., FDA approves Eli Lilly's baricitinib. *Nature Reviews Drug Discovery* **2018**, 17 (7), 460. DOI: 10.1038/nrd.2018.112.

222. National Institute of Allergy and Infectious Diseases (NIAID) Office of Communications. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19 *NIAID News Releases* [Online], April 29, 2020. <https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19> (accessed June 2020).
223. Tchesnokov, E. P.; Feng, J. Y.; Porter, D. P.; Götte, M., Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. *Viruses* **2019**, *11* (4), 326. DOI: 10.3390/v11040326.
224. Halford, B., An emerging antiviral takes aim at COVID-19. *C&EN Global Enterprise* **2020**, *98* (20), 22-23. DOI: 10.1021/cen-09820-feature2.
225. U.S. National Library of Medicine. Studies found for COVID-19 and EIDD-2801 *ClinicalTrials.gov* [Online], 2020. <https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=EIDD-2801> (accessed June 2020).
226. Cross, R., Merck & Co. joins race for COVID-19 vaccines and therapies. *C&EN Global Enterprise* **2020**, *98* (21), 12. DOI: 10.1021/cen-09821-buscon1.
227. Jena, N. R., Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2. *Chemical Physics Impact* **2021**, *2*, 100011. DOI: 10.1016/j.chphi.2021.100011.
228. Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qi, F.; Guo, L.; Huang, C.; Jia, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine* **2020**, *382* (19), 1787-1799. DOI: 10.1056/NEJMoa2001282.
229. Sarma, P.; Prajapati, M.; Avti, P.; Kaur, H.; Kumar, S.; Medhi, B., Therapeutic options for the treatment of 2019 novel coronavirus: An evidence-based approach. *Indian Journal of Pharmacology* **2020**, *52* (1), 1-5. DOI: 10.4103/ijp.IJP_119_20.
230. Nguyen, B. C. Q.; Yoshimura, K.; Kumazawa, S.; Tawata, S.; Maruta, H., Frondoside A from sea cucumber and nymphaeols from Okinawa propolis: Natural anti-cancer agents that selectively inhibit PAK1 *in vitro*. *Drug Discoveries & Therapeutics* **2017**, *11* (2), 110-114. DOI: 10.5582/ddt.2017.01011.
231. Korkmaz, B.; Lesner, A.; Marchand-Adam, S.; Moss, C.; Jenne, D. E., Lung protection by cathepsin C inhibition: A new hope for COVID-19 and ARDS? *Journal of Medicinal Chemistry* **2020**, *63* (22), 13258-13265. DOI: 10.1021/acs.jmedchem.0c00776.
232. Boerner, L. K., Cell studies follow up on previous SARS-CoV-2 studyCell studies follow up on previous SARS-CoV-2 study. *C&EN Global Enterprise* **2020**, *98* (18), 5. DOI: 10.1021/cen-09818-leadcon.

233. Gordon, D. E.; Jang, G. M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K. M.; O'Meara, M. J.; Rezelj, V. V.; Guo, J. Z.; Swaney, D. L.; Tummino, T. A.; Huettenhain, R.; Kaake, R. M.; Richards, A. L.; Tutuncuoglu, B.; Foussard, H.; Batra, J.; Haas, K.; Modak, M.; Kim, M.; Haas, P.; Polacco, B. J.; Braberg, H.; Fabius, J. M.; Eckhardt, M.; Soucheray, M.; Bennett, M. J.; Cakir, M.; McGregor, M. J.; Li, Q.; Meyer, B.; Roesch, F.; Vallet, T.; Mac Kain, A.; Miorin, L.; Moreno, E.; Naing, Z. Z. C.; Zhou, Y.; Peng, S.; Shi, Y.; Zhang, Z.; Shen, W.; Kirby, I. T.; Melnyk, J. E.; Chiorba, J. S.; Lou, K.; Dai, S. A.; Barrio-Hernandez, I.; Memon, D.; Hernandez-Armenta, C.; Lyu, J.; Mathy, C. J. P.; Perica, T.; Pilla, K. B.; Ganesan, S. J.; Saltzberg, D. J.; Rakesh, R.; Liu, X.; Rosenthal, S. B.; Calviello, L.; Venkataramanan, S.; Liboy-Lugo, J.; Lin, Y.; Huang, X.-P.; Liu, Y.; Wankowicz, S. A.; Bohn, M.; Safari, M.; Ugur, F. S.; Koh, C.; Savar, N. S.; Tran, Q. D.; Shengjuler, D.; Fletcher, S. J.; O'Neal, M. C.; Cai, Y.; Chang, J. C. J.; Broadhurst, D. J.; Klippsten, S.; Sharp, P. P.; Wenzell, N. A.; Kuzuoglu, D.; Wang, H.-Y.; Trenker, R.; Young, J. M.; Caverio, D. A.; Hiatt, J.; Roth, T. L.; Rathore, U.; Subramanian, A.; Noack, J.; Hubert, M.; Stroud, R. M.; Frankel, A. D.; Rosenberg, O. S.; Verba, K. A.; Agard, D. A.; Ott, M.; Emerman, M.; Jura, N.; von Zastrow, M.; Verdin, E.; Ashworth, A.; Schwartz, O.; d'Enfert, C.; Mukherjee, S.; Jacobson, M.; Malik, H. S.; Fujimori, D. C.; Ideker, T.; Craik, C. S.; Floor, S. N.; Fraser, J. S.; Gross, J. D.; Sali, A.; Roth, B. L.; Ruggero, D.; Taunton, J.; Kortemme, T.; Beltrao, P.; Vignuzzi, M.; Garcia-Sastre, A.; Shokat, K. M.; Shoichet, B. K.; Krogan, N. J., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* **2020**, 583, 459-468. DOI: 10.1038/s41586-020-2236-9.
234. Freedberg, D. E.; Conigliaro, J.; Wang, T. C.; Tracey, K. J.; Callahan, M. V.; Abrams, J. A.; Sobieszczyk, M. E.; Markowitz, D. D.; Gupta, A.; O'Donnell, M. R.; Li, J.; Tuveson, D. A.; Jin, Z.; Turner, W. C.; Landry, D. W., Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. *Gastroenterology* **2020**, 159 (3), 1129-1131, e1-e3. DOI: 10.1053/j.gastro.2020.05.053.
235. Malone, R.; Tisdall, P.; Fremont-Smith, P.; Liu, Y.; Huang, X.-P.; White, K.; Miorin, L.; Olmo, E. M. D.; Alon, A.; Delaforge, E.; Heinecker, C.; Wang, G.; Pottel, J.; Bona, R.; Smith, N.; Hall, J.; Shapiro, G.; Clark, H.; Mattermaier, A.; Kruse, A.; Garcia-Sastre, A.; Roth, B.; Glasspool-Malone, J.; Francone, V.; Herzog, N.; Fremont-Smith, M.; Rieke, D., COVID-19: Famotidine, histamine, mast cells, and mechanisms. *Research Square* **2020**, (Preprint), PPR179097. DOI: 10.21203/rs.3.rs-30934/v3.
236. Horby, P.; Landray, M.; University of Oxford. Nuffield Department of Public Health. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 *Randomised Evaluation of COVid-19 thERapy (RECOVERY): News* [Online], June 16, 2020. <https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19> (accessed June 20, 2020).
237. Borba, M. G. S.; Val, F. F. A.; Sampaio, V. S.; Alexandre, M. A. A.; Melo, G. C.; Brito, M.; Mourão, M. P. G.; Brito-Sousa, J. D.; Baía-da-Silva, D.; Guerra, M. V. F.; Hajjar, L. A.; Pinto, R. C.; Balieiro, A. A. S.; Pacheco, A. G. F.; Santos, J. D. O., Jr; Naveca, F. G.; Xavier, M. S.; Siqueira, A. M.; Schwarzbald, A.; Croda, J.; Nogueira, M. L.; Romero, G. A. S.; Bassat, Q.; Fontes, C. J.; Albuquerque, B. C.; Daniel-Ribeiro, C.-T.; Monteiro, W. M.; Lacerda, M. V. G., Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. *JAMA Network Open* **2020**, 3 (4), e208857. DOI: 10.1001/jamanetworkopen.2020.8857.

238. Fiolet, T.; Guihur, A.; Rebeaud, M. E.; Mulot, M.; Peiffer-Smadja, N.; Mahamat-Saleh, Y., Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. *Clinical Microbiology and Infection* **2021**, 27 (1), 19-27. DOI: 10.1016/j.cmi.2020.08.022.
239. Magagnoli, J.; Narendran, S.; Pereira, F.; Cummings, T. H.; Hardin, J. W.; Sutton, S. S.; Ambati, J., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. *Med* **2020**, 1 (1), 114-127.e3. DOI: 10.1016/j.medj.2020.06.001.
240. Singh, S.; Khan, A.; Chowdhry, M.; Chatterjee, A., Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States- Real-world evidence from a federated electronic medical record network. *medRxiv* **2020**, (Preprint), 20099028. DOI: 10.1101/2020.05.12.20099028.
241. McCoy, M., Lilly to test baricitinib against COVID-19. *C&EN Global Enterprise* **2020**, 98 (15), 13. DOI: 10.1021/cen-09815-buscon17.
242. Halford, B., Ruxolitinib to be tested in fight against COVID-19. *C&EN Global Enterprise* **2020**, 98 (14), 11. DOI: 10.1021/cen-09814-buscon3.
243. Zhang, C.; Wu, Z.; Li, J.-W.; Zhao, H.; Wang, G.-Q., Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *International Journal of Antimicrobial Agents* **2020**, 55 (5), 105954. DOI: 10.1016/j.ijantimicag.2020.105954.
244. Boerner, L. K., Rethinking the role of blood pressure drugs in COVID-19. *C&EN Global Enterprise* **2020**, 98 (20), 29-33. DOI: 10.1021/cen-09820-cover.
245. Lo, K. B.; McCullough, P. T.; Kangaswami, J., Antihypertensive drugs and risk of COVID-19? *The Lancet Respiratory Medicine* **2020**, 8 (5), e29. DOI: 10.1016/S2213-2600(20)30156-9.
246. Perrotta, F.; Matera, M. G.; Cazzola, M.; Bianco, A., Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? *Respiratory Medicine* **2020**, 168 (July), 105996. DOI: 10.1016/j.rmed.2020.105996.
247. Imai, Y.; Kuba, K.; Rao, S.; Huan, Y.; Guo, F.; Guan, B.; Yang, P.; Sarao, R.; Wada, T.; Leong-Poi, H.; Crackower, M. A.; Fukamizu, A.; Hui, C.-C.; Hein, L.; Uhlig, S.; Slutsky, A. S.; Jiang, C.; Penninger, J. M., Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* **2005**, 436 (7047), 112-116. DOI: 10.1038/nature03712.
248. Kuba, K.; Imai, Y.; Rao, S.; Gao, H.; Guo, F.; Guan, B.; Huan, Y.; Yang, P.; Zhang, Y.; Deng, W.; Bao, L.; Zhang, B.; Liu, G.; Wang, Z.; Chappell, M.; Liu, Y.; Zheng, D.; Leibbrandt, A.; Wada, T.; Slutsky, A. S.; Liu, D.; Qin, C.; Jiang, C.; Penninger, J. M., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nature Medicine* **2005**, 11 (8), 875-879. DOI: 10.1038/nm1267.
249. Götz, V.; Magar, L.; Dornfeld, D.; Giese, S.; Pohlmann, A.; Höper, D.; Kong, B.-W.; Jans, D. A.; Beer, M.; Haller, O.; Schwemmler, M., Influenza A viruses escape from MxA restriction at

the expense of efficient nuclear vRNP import. *Scientific Reports* **2016**, 6 (1), 23138. DOI: 10.1038/srep23138.

250. U.S. National Library of Medicine. Studies found for COVID-19 and ACE2 *ClinicalTrials.gov* [Online], 2020. ClinicalTrials.gov. <https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=ACE2> (accessed June 2020).

251. Tian, X.; Li, C.; Huang, A.; Xia, S.; Lu, S.; Shi, Z.; Lu, L.; Jiang, S.; Yang, Z.; Wu, Y.; Ying, T., Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerging Microbes & Infections* **2020**, 9 (1), 382-385. DOI: 10.1080/22221751.2020.1729069.

252. Pinto, D.; Park, Y.-J.; Beltramello, M.; Walls, A. C.; Tortorici, M. A.; Bianchi, S.; Jaconi, S.; Culap, K.; Zatta, F.; De Marco, A.; Peter, A.; Guarino, B.; Spreafico, R.; Camerini, E.; Case, J. B.; Chen, R. E.; Havenar-Daughton, C.; Snell, G.; Telenti, A.; Virgin, H. W.; Lanzavecchia, A.; Diamond, M. S.; Fink, K.; Veasler, D.; Corti, D., Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **2020**, 583 (7815), 290-295. DOI: 10.1038/s41586-020-2349-y.

253. Sesterhenn, F.; Yang, C.; Bonet, J.; Cramer, J. T.; Wen, X.; Wang, Y.; Chiang, C.-I.; Abriata, L. A.; Kucharska, I.; Castoro, G.; Vollers, S. S.; Galloux, M.; Dheilly, E.; Rosset, S.; Corthésy, P.; Georgeon, S.; Villard, M.; Richard, C. A.; Descamps, D.; Delgado, T.; Oricchio, E.; Rameix-Welti, M.-A.; Más, V.; Ervin, S.; Elouët, J.-F.; Riffault, S.; Bates, J. T.; Julien, J.-P.; Li, Y.; Jardetzky, T.; Krey, T.; Correia, B. E., *De novo* protein design enables the precise induction of RSV-neutralizing antibodies. *Science* **2020**, 368 (6492), eaay5051. DOI: 10.1126/science.aay5051.

254. Whittaker, G. R.; Daniel, S., Going back in time for an antibody to fight COVID-19. *Nature* **2020**, 583 (7815), 203-204. DOI: 10.1038/d41586-020-01816-5.

255. Kasem, S.; Qasim, I.; Al-Hufofi, A.; Hashim, O.; Alkarar, A.; Abu-Obeida, A.; Gaafer, A.; Elfadil, A.; Zaki, A.; Al-Romani, A.; Babekr, N.; El-Harby, N.; Hussien, R.; Al-Sahaf, A.; Al-Doweriej, A.; Bayoumi, F.; Poon, L. L. M.; Chu, D. K. W.; Peiris, M.; Perera, R. A. P. M., Cross-sectional study of MERS-CoV-specific RNA and antibodies in animals that have had contact with MERS patients in Saudi Arabia. *Journal of Infection and Public Health* **2018**, 11 (3), 331-338. DOI: 10.1016/j.jiph.2017.09.022.

256. Prompetchara, E.; Ketloy, C.; Palaga, T., Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. *Asian Pacific Journal of Allergy and Immunology* **2020**, 38 (1), 1-9. DOI: 10.12932/ap-200220-0772.

257. Yuan, M.; Wu, N. C.; Zhu, X.; Lee, C.-C. D.; So, R. T. Y.; Lv, H.; Mok, C. K. P.; Wilson, I. A., A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science* **2020**, 368 (6491), 630-633. DOI: 10.1126/science.abb7269.

258. Cross, R., U.S. preorders COVID-19 vaccine and antibody therapy. *C&EN Global Enterprise* **2020**, 98 (27), 11. DOI: 10.1021/cen-09827-buscon2.

259. Jarvis, L. M., Lilly antibody shows promise in COVID-19. *C&EN Global Enterprise* **2020**, 98 (36), 15. DOI: 10.1021/cen-09836-buscon14.
260. Antibody Society Archives for COVID-19 on Welcome to the Antibody Society. <https://www.antibodysociety.org/covid-19/> (accessed August 2020).
261. Kelley, B., Developing therapeutic monoclonal antibodies at pandemic pace. *Nature Biotechnology* **2020**, 38 (5), 540-545. DOI: 10.1038/s41587-020-0512-5.
262. Iwasaki, A.; Omer, S. B., Why and How Vaccines Work. *Cell* **2020**, 183 (2), 290-295. DOI: 10.1016/j.cell.2020.09.040.
263. Lin, F.; Xu, J.; Shi, J.; Li, H.; Li, B., Molecular cloning and characterization of a novel glyoxalase I gene TaGly I in wheat (*Triticum aestivum* L.). *Molecular Biology Reports* **2010**, 37 (2), 729-35. DOI: 10.1007/s11033-009-9578-3.
264. Callaway, E., COVID vaccine boosters: the most important questions. *Nature* **2021**, 596 (7871), 178-180. DOI: 10.1038/d41586-021-02158-6.
265. Boukhatem, M. N.; Setzer, W. N., Aromatic herbs, medicinal plant-derived essential oils, and phytochemical extracts as potential therapies for coronaviruses: Future perspectives. *Plants (Basel)* **2020**, 9 (6), 800. DOI: 10.3390/plants9060800.
266. Le, T. T.; Andreadakis, Z.; Kumar, A.; Gómez Román, R.; Tollefsen, S.; Saville, M.; Mayhew, S., The COVID-19 vaccine development landscape. *Nature Reviews Drug Discovery* **2020**, 19 (5), 305-306. DOI: 10.1038/d41573-020-00073-5.
267. McKeever, A.; National Geographic Staff. Here's the latest on COVID-19 vaccines: Everything you need to know about the COVID-19 vaccines—from their safety and efficacy to the global vaccine rollout. *National Geographic Science: Coronavirus Coverage* [Online], August 20, 2021. <https://www.nationalgeographic.com/science/health-and-human-body/human-diseases/coronavirus-vaccine-tracker-how-they-work-latest-developments-cvd/> (accessed August 21, 2020).
268. O'Callaghan, K. P.; Blatz, A. M.; Offit, P. A., Developing a SARS-CoV-2 vaccine at warp speed. *JAMA* **2020**, 324 (5), 437-438. DOI: 10.1001/jama.2020.12190.
269. World Health Organization COVID-19 vaccine tracker and landscape. <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines> (accessed October 28, 2020).
270. Nishiura, H.; Kobayashi, T.; Yang, Y.; Hayashi, K.; Miyama, T.; Kinoshita, R.; Linton, N. M.; Jung, S.-m.; Yuan, B.; Suzuki, A.; Akhmetzhanov, A. R., The rate of underascertainment of novel coronavirus (2019-nCoV) infection: Estimation using Japanese passengers data on evacuation flights. *Journal of Clinical Medicine* **2020**, 9 (2), 419. DOI: 10.3390/jcm9020419.
271. Eikenberry, S. E.; Mancuso, M.; Iboi, E.; Phan, T.; Eikenberry, K.; Kuang, Y.; Kostelich, E.; Gumel, A. B., To mask or not to mask: Modeling the potential for face mask use by the

general public to curtail the COVID-19 pandemic. *Infectious Disease Modelling* **2020**, 5, 293-308. DOI: 10.1016/j.idm.2020.04.001.

272. Zhao, M.; Liao, L.; Xiao, W.; Yu, X.; Wang, H.; Wang, Q.; Lin, Y. L.; Kilinc-Balci, F. S.; Price, A.; Chu, L.; Chu, M. C.; Chu, S.; Cui, Y., Household materials selection for homemade cloth face coverings and their filtration efficiency enhancement with triboelectric charging. *Nano Letters* **2020**, 20 (7), 5544-5552. DOI: 10.1021/acs.nanolett.0c02211.

273. Lin, Q.; Lim, J. Y. C.; Xue, K.; Yew, P. Y. M.; Owh, C.; Chee, P. L.; Loh, X. J., Sanitizing agents for virus inactivation and disinfection. *View* **2020**, 1 (2), e16. DOI: 10.1002/viw2.16.

274. Konda, A.; Prakash, A.; Moss, G. A.; Schmoldt, M.; Grant, G. D.; Guha, S., Aerosol filtration efficiency of common fabrics used in respiratory cloth masks. *ACS Nano* **2020**, 14 (5), 6339-6347. DOI: 10.1021/acsnano.0c03252.

275. Wood-Black, F.; Lewin, J.; Blayney, M. B.; Galindo, J.; Foreman, R.; Zelivyanskaya, M.; Reid, M., Highlights: Reusing masks, face covering efficacy, plant restarts, and more. *ACS Chemical Health & Safety* **2020**, 27 (4), 204-208. DOI: 10.1021/acs.chas.0c00069.

276. Bettenhausen, C. A., A chemist's guide to disinfectants. *C&EN Global Enterprise* **2020**, 98 (20), 24-25. DOI: 10.1021/cen-09820-feature?.